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teine proteases, generally inhibiting all serine proteases, and 
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TRIPEPTIDE a-KETOAMIDES 
This is a continuation-in-part of application(s) Ser. No. 
08/539,944 filed on Oct. 6, 1995, now U.S. Pat. No. 5,650, 
508 which is a continuation of Ser. No. 8/246,511, filed on 
May 20, 1994, now abandoned; which is a continuation of 
Ser. No. 08/118,997, filed Sep. 9, 1993, now abandoned; 
which is a continuation of Ser. No. 07/815,073, filed Dec. 
27, 1991, now abandoned. 
BACKGROUND OF THE INVENTION 
1. Field of the Invention 
This invention relates to a novel class of peptide ketoa-
mides useful for selectively inhibiting serine proteases, 
selectively inhibiting cysteine proteases, generally inhibit-
ing all serine proteases, and generally inhibiting all cysteine 
proteases. Serine proteases and cysteine proteases are 
involved in numerous disease states and inhibitors for these 
enzymes can be used therapeutically for the treatment of 
diseases involving serine proteases or cysteine proteases. We 
have discovered that peptide a-ketoamides can be con-
structed to inhibit selectively individual serine or cysteine 
proteases or groups of serine or cysteine proteases. We have 
found that peptide ketoamides which contain hydrophobic 
aromatic amino acid residues in the P 1 site are potent 
inhibitors of chymases and chymotrypsin-like enzymes. 
Ketoamides containing small hydrophobic amino acid resi-
dues at the P 1 position are good inhibitors of elastases. 
Inhibitors of elastases and chymases are useful as anti-
infiammatory agents. We show that peptide ketoamides 
which contain cationic amino acid residues such as Arg and 
Lys in the P 1 site will be potent inhibitors of trypsin and 
blood coagulation enzymes. These inhibitors are thus useful 
as anticoagulants. Cysteine proteases such as papain, cathe-
psin B, and calpain I and II are also inhibited by ketoamides. 
Keto amides with aromatic amino acid residues in the P 1 site 
are good inhibitors for cathepsin B and papain. Thus, they 
would have utility as anticancer agents. Ketoamides with 
either aromatic amino acid residues or small hydrophobic 
alkyl amino acid residues at P 1 are good inhibitors of calpain 
I and II. These inhibitors are useful as neuroprotectants and 
can be used as therapeutics for the treatment of neurode-
generation and stroke. 
2. Nomenclature 
In discussing the interactions of peptides with serine and 
cysteine proteases, we have utilized the nomenclature of 
Schechter and Berger [Biochem. Biophys. Res. Commun. 27, 
157-162 (1967); incorporated herein by reference]. The 
individual amino acid residues of a substrate or inhibitor are 
designated P 1, P 2 , etc. and the corresponding subsites of the 
enzyme are designated S1, S2 , etc. The scissile bond of the 
substrate is S1-S/ The primary substrate recognition site of 
serine proteases is S1. The most important recognition 
subsites of cysteine proteases are S1 and S2 . 
Amino acid residues and blocking groups are designated 
using standard abbreviations [see J. Biol. Chem. 260, 14-42 
(1985) for nomenclature rules; incorporated herein by 
reference]. An amino acid residue (AA) in a peptide or 
inhibitor structure refers to the part structure -NH-
CHR1-CO-, where R1 is the side chain of the amino acid 
residue AA. A peptide a-ketoester residue would be desig-
nated -AA-CO-OR which represents the part structure 
-NH-CHR1-CO-CO-OR. Thus, the ethyl ketoester 
derived from benzoyl alanine would be designated 
Bz-Ala-CO-OEt which represents C6H5CO-NH-
CHMe-CO-CO-OEt. Peptide ketoamide residues 
2 
would be designated -AA-CO-NH-R. Thus, the ethyl 
keto amide derived from Z-Leu-Phe-OH would be 
designated Z-Leu-Phe-CO-NH-Et which represents 
C6H5 CH2 0CO-NH-CH(CH2 CHMe2)-CO-NH-CH 
5 (CH2Ph)-CO-CO-NH-Et. 
3. Description of the Related Art 
Cysteine Proteases 
Cysteine proteases such as calpain use a cysteine residue 
in their catalytic mechanism in contrast to serine proteases 
10 which utilize a serine residue. Cysteine proteases include 
papain, cathepsin B, calpains, and several viral enzymes. 
Neural tissues, including brain, are known to possess a large 
variety of proteases, including at least two calcium stimu-
lated proteases termed calpains. Calpains are present in 
15 many tissues in addition to the brain. Calpain I is activated 
by micromolar concentrations of calcium while calpain II is 
activated by millimolar concentrations. In the brain, calpain 
II is the predominant form, but calpain I is found at synaptic 
endings and is thought to be the form involved in long term 
20 potentiation, synaptic plasticity, and cell death Other Ca2+ 
activated cysteine proteases may exist, and the term 
"calpain" is used to refer to all Ca2+ activated cysteine 
proteases, including calpain I and calpain II. The terms 
"calpain I" and "calpain II" are used herein to refer to the 
25 micromolar and millimolar activated calpains, respectively, 
as described above. While calpains degrade a wide variety of 
protein substrates, cytoskeletal proteins seem to be particu-
larly susceptible to attack. In some cases, the products of the 
proteolytic digestion of these proteins by calpain are dis-
30 tinctive and persistent over time. Since cytoskeletal proteins 
are major components of certain types of cells, this provides 
a simple method of detecting calpain activity in cells and 
tissues. Thus, calpain activation can be measured indirectly 
by assaying the proteolysis of the cytoskeletal protein 
35 spectrin, which produces a large, distinctive and biologically 
persistent breakdown product when attacked by calpain 
[Siman, Baudry, and Lynch, Proc. Natl. Acad. Sci. USA 81, 
3572-3576 (1984); incorporated herein by reference]. Acti-
vation of calpains and/or accumulation of breakdown prod-
40 ucts of cytoskeletal elements has been observed in neural 
tissues of mammals exposed to a wide variety of neurode-
generative diseases and conditions. For example, these phe-
nomena have been observed following ischemia in gerbils 
and rats, following stroke in humans, following administra-
45 tion of the toxins kainate, trimethyltin or colchicine in rats, 
and in human Alzheimer's disease. 
Several inhibitors of calpain have been described includ-
ing peptide aldehydes such asAc-Leu-Leu-Nle-H and 
leupeptin (Ac-Leu-Leu-Arg-H), as well as epoxysuc-
50 cinates such as E-64. These compounds are not especially 
useful at inhibiting calpain in neural tissue in vivo because 
they are poorly membrane permeant and, accordingly, are 
not likely to cross the blood brain barrier very well. Also, 
many of these inhibitors have poor specificity and will 
55 inhibit a wide variety of proteases in addition to calpain. 
Other classes of compounds which inhibit cysteine proteases 
include peptide diazomethyl ketone (Rich, D. H., in Pro-
tease Inhibitors, Barrett A. J., and Salversen, G., Eds., 
Elsevier, New York, 1986, pp 153-178; incorporated herein 
60 by reference). Peptide diazomethyl ketones are potentially 
carcinogenic and are thought to be poorly membrane per-
meant and to have low specificity. Thus, no effective therapy 
has yet been developed for most neurodegenerative diseases 
and conditions. Millions of individuals suffer from neuro-
65 degenerative diseases and thus, there is a need for therapies 
effective in treating and preventing these diseases and con-
ditions. 
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Cathepsin B is involved in muscular dystrophy, myocar-
dial tissue damage, tumor metastasis, and bone resorption. 
4 
Scientific Publications, (1982); incorporated herein by 
reference]. In the treatment of patients with coagulation 
problems, anticoagulant or antithrombotic agents of diverse 
mechanisms are urgently sought in order to provide better 
In addition, a number of viral processing enzymes, which 
are essential for viral infection, are cysteine proteases, 
inhibitors of cysteine proteases would have multiple thera-
peutic uses. 
Serine Proteases 
Serine proteases play critical roles in several physiologi-
5 medical care. Inhibitors for the trypsin-like enzymes 
involved in blood coagulation are useful anticoagulants in 
vivo [see for example: H-D-Phe-Pro-Arg-CH2 Cl, 
Hanson and Harker, Proc. Natl. Acad. Sci. 85, 3184-3188 
(1988); 7-Amino-4-chloro-3-(3-isothiureidopropoxy) cal processes such as digestion, blood coagulation, comple-
ment activation, fibrinolysis, viral infection, fertilization, 
and reproduction. Serine proteases are not only a physi-
ological necessity, but also a potential hazard if they are not 
controlled. Uncontrolled proteolysis by elastases may cause 
pancreatitis, emphysema, rheumatoid artritis, bronchial 
inflammation and adult respiratory distress syndrome. It has 15 
been suggested that a new trypsin-like cellular enzyme 
(tryptase) is involved in the infection of human immunode-
ficiency virus type 1 [HIV-1; Hattori et al., FEES Letters 
248, pp. 48-52 (1989)], which is a causative agent of 
acquired immunodeficiency syndrome (AIDS). Plasmin is 20 
involved in twnor invasiveness, tissue remodeling, 
blistering, and clot dissociation. Accordingly, specific and 
selective inhibitors of these proteases should be potent 
anticoagulants, anti-inflammtory agents, anti-tumor agents 
and anti-viral agents usefull in the treatment of protease- 25 
related diseases [Powers and Harper, Proteinase Inhibitors, 
10 isocoumarin (ACITIC), Oweida, Ku, Lumsden, Kam, and 
Powers, Thrombos. Res. 58, 191-197 (1990); incorporated 
herein by reference]. 
pp 55-152, Barrett and Salvesen, eds., Elsevier, (1986); 
incorporated herein by reference]. In vitro proteolysis by 
chymotrypsin, trypsin or the elastase family is a serious 
problem in the production, purification, isolation, transport 30 
or storage of peptides and proteins. 
Elastase inhibitors are anti-inflammatory agents which 
can be used to treat elastase-associated inflammation includ-
ing rheumatoid arthritis and emphysema Although the natu-
rally occurring protease inhibitor, al-protease inhibitor (al- 35 
PI) has been used to treat patients with emphysema, this 
protein inhibitor is not widely used clinically due to the high 
dosage needed for treatment and the difficulty of producing 
large quantities. Therefore, small molecular weight elastase 
inhibitors are needed for therapy. Other low molecular 40 
weight elastase inhibitors have utility for the treatment of 
emphysema and inflammation (see: l-carpapenem-3-
carboxylic esters as anti-inflammatory agents, U.S. Pat. No. 
4,493,839; N-carboxyl-thienamycin esters and analogs 
thereof as anti-inflammatory agents, U.S. Pat. No. 4,495, 45 
197; incorporated herein by reference). 
Anticoagulants and antithrombotic drugs are used in a 
variety of thrombotic disorders. The 1990 Physician's Desk 
Reference lists several anticoagulant drugs (heparin, prota-
mine sulfate and warfarin), a few antiplatelet drugs (aspirin) 50 
and several thrombolytic agents. Heparin and warfarin are 
commonly used clinically for prevention and treatment of 
venous thrombosis and pulmonary embolism. Heparin 
inhibits the blood coagulation activity by accelerating the 
binding of natural plasma protease inhibitor antithrombin III 55 
with coagulation factors, and warfarin acts as a vitamin K 
antagonist and inhibits the synthesis of coaguation factors. 
None of the anticoagulant drugs, antithrombotic drugs, 
fibrinolytic agents and antiplatelet drugs are highly effective 
in all clinical situations and many induce side reactions [Von 60 
Kaulla, Burger's Medicinal Chemistry, Part II, pp 
1081-1132, Wolff, ed., (1979); incorporated herein by 
reference]. Coagulation disorders such as disseminated 
intravascular coagulation, bleeding complications of medi-
cal and surgical procedures and bleeding complications of 65 
systemic illness are still difficult to manage [Ingram, Bro-
zovic and Slater, Bleeding Disorders, pp 1-413, Blackwell 
Ketoesters 
A few amino acid and peptide ketoesters and ketoacids 
have been previously reported. Cornforth and Cornforth [J. 
Chem. Soc., 93-96 (1953); incorporated herein by reference] 
report the synthesis of the ketoacids PhCH2CO-Gly-
CO-OH and Ac-Gly-CO-OH upon hydrolysis of het-
erocyclic molecules. Charles et al. [J. Chem. Soc. Perkin I, 
1139-1146 (1980); incorporated herein by reference] use 
ketoesters for the synthesis of bicyclic heterocycles. They 
report the synthesis of n-BuCO-Ala-CO-OEt, 
PrCO-Ala-CO-OEt, cyclopentylCO-Ala-CO-OEt, 
PrCO-PhGly-CO-OEt, and Bz-Ala-CO-OEt. Hori 
et al. [Peptides: Structure and Function-Proceedings of the 
Ninth American Peptide Symposium (Deber, Hruby, and 
Kopple, Eds.) Pierce Chemical Co., pp 819-822 (1985); 
incorporated herein by reference] report Bz-Ala-C0-
0 Et, Bz-Ala-CO-OH, Z-Ala-Ala-Abu-CO-
OEt, Z-Ala-Ala-Abu-CO-OBzl, and Z-Ala-
Ala-Ala-Ala-CO-OEt (Abu=2-aminobutanoic acid or 
a-aminobutyric acid) and report that these compounds 
inhibit elastase. Trainer [Trends Pharm. Sci. 8, 303-307 
(1987); incorporated herein by reference] comments on one 
of this compounds. Burkhart, J., Peet, N. P., and Bey, P. 
[Tetrahedron Lett. 29, 3433-3436 (1988); incorporated 
herein by reference] report the synthesis of Z-Val-Phe-
CO-OMe and Bz-Phe-CO-OMe. 
Mehdi et al., [Biochem. Biophys. Res. Comm. 166, 
595-600 (1990); incorporated herein by reference] report 
the inhibition of human neutrophil elastase and cathepsin G 
by peptide a-ketoesters. Angelastro et al., [J. Med. Chem. 
33, 13-16 (1990); incorporated herein by reference] report 
some a-ketoesters which are inhibitors of calpain and chy-
motrypsin. Hu and Abeles [Arch. Biochem. Biophys. 281, 
271-274 (1990)]; incorporated herein by reference] report 
some peptidyl a-ketoamides and a-ketoacids which are 
inhibitors of cathepsin B and papain. Peet et al. [J. Med. 
Chem. 33, 394-407 (1990); incorporated herein by 
reference] report some peptidyl a-ketoesters which are 
inhibitors of porcine pancreatic elastase, human neutrophil 
elastase, and rat & human neutrophil cathepsin G. 
Keto amides 
A single peptide ketoamide is reported in the literature by 
Hu and Abeles [Arch. Biochem. Biophys. 281, 271-274 
(1990)]. This compound Z-Phe-NHCH2 CO-CO-
NH-Et or Z-Phe-Gly-CO-NH-Et is reported to be 
an inhibitor of papain (KI=l.5 µM) and cathepsin B (KI=4 
µM). 
SUMMARY OF THE INVENTION 
We have discovered that peptide and amino acid 
a-ketoamide derivatives are a novel group of inhibitors for 
serine proteases and cysteine proteases. Inhibitors are com-
pounds that reduce or eliminate the catalytic activity of the 
enzyme. We have discovered that peptide a-ketoamide 
US 6,235,929 Bl 
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ing amino acid residues with hydrophobic side chain at the 
P 1 site have also been found to be excellent inhibitors of 
several cysteine proteases including papain, cathepsin B, 
calpain I, and calpain II. These structures may be used in 
derivatives, which have an amino acid sequence similar to 
that of good substrates for a particular protease, are good 
inhibitors for that protease. Thus, we are able to predict the 
structures of new inhibitors for other serine and cysteine 
proteases based on knowledge of their substrate specificities. 
We have discovered some peptide a-ketoamide deriva-
tives which are specific inhibitors for chymotrypsin. Chy-
motrypsin and chymotrypsin-like enzymes hydrolyze pep-
tide bonds where P 1 amino acid is Trp, Tyr, Phe, Met, Leu 
5 vivo to treat diseases such as emphysema, adult respiratory 
distress syndrome, rheumatoid arthritis and pancreatitis 
which result from uncontrolled proteolysis by elastase, 
chymotrypsin, trypsin and related serine proteases. These 
inhibitors may be used in vitro to prevent proteolysis which 
10 
occurs in the process of production, isolation, purification, 
storage or transport of peptides and proteins. These inhibi-
tors may be useful as therapeutic agents for treatment of 
neurodegeneration, viral infections, muscular dystrophy, 
myocardial tissue damage, tumor metastasis, and bone 
or other amino acid residues which contain aromatic or large 
alkyl side chains. Inhibitors with these residues at P 1 are 
good chymotrypsin and chymase inhibitors. Trypsin and 
trypsin-like enzymes normally cleave peptide bonds in pro-
teins and peptides where the amino acid residue on the 
carbonyl side of the split bond (P 1 residue) is Lys or Arg. We 15 
show that peptide a-ketoamide derivatives which have Lys 
or Arg at P 1 will be good inhibitors for these enzymes. 
Elastase and elastase-like enzymes cleave peptide bonds 
where the P 1 amino acid is Ala, Val, Ser, Leu and other 
similar amino acids. We shown that inhibitors with these 20 
residues at P 1 are good elastase inhibitors. All of the above 
enzymes have extensive secondary specificity and recognize 
amino acid residues removed from the P1 residue. 
The peptide a-ketoamide derivatives are also novel and 
potent inhibitors of cysteine proteases including calpains 25 
and cathepsin B. The calpain inhibitors are useful for 
treatment of various neurodegenerative diseases and 
conditions, including ischemia, stroke, and Alzheimer's 
disease. 
The new protease inhibitors, especially the elastase 
30 
inhibitors, trypsin inhibitors, and chymase inhibitors are 
useful for controlling tissue damage and various inflamma-
tory conditions mediated by proteases such as blistering. The 
inhibitors for blood coagulation enzymes will be useful 35 
anticoagulants and could be used to treat thrombosis. 
The peptide and amino acid a-ketoamide derivatives are 
also useful in vitro for inhibiting trypsin, elastase, chymo-
typsin and other serine proteases of similar specificity, and 
for inhibiting serine proteases in general. The inhibitors can 40 
be used to identify new proteolytic enzymes encountered in 
research. They can also be used in research and industrially 
to prevent undesired proteolysis that occurs during the 
production, isolation, purification, transport and storage of 
valuable peptides and proteins. Such proteolysis often 45 
destroys or alters the activity and/or function of the peptides 
and proteins. Uses would include the addition of the inhibi-
tors to antibodies, enzymes, plasma proteins, tissue extracts 
or other proteins and peptides which are widely sold for use 
in clinical analyses, biomedical research, and for many other 50 
reasons. For some uses a specific inhibitor would be 
desirable, while in other cases, an inhibitor with general 
specificity would be preferred. 
resorption. 
The novel class of dipeptide a-ketoamides have the 
following structural formula: 
or a pharmaceutically acceptable salt, wherein 
M1 represents H, NH2-CO, NH2-CS-, NH2-S02-, 
X-NH-CO-, X2 N-CO-, X-NH-CS-, X2N-
CS-, X-NH-S0 2-, X 2 N-S0 2-, X-CO-, 
X-CS-, X-S02-, X-0-CO-, or X-0-CS-; 
X is selected from the group consisting of C1 _10 alkyl, 
cl-10 fiuoroalkyl, cl-10 alkyl substituted with J, cl-10 fiuo-
roalkyl substituted with J, 1-admantyl, 9-fiuorenyl, phenyl, 
phenyl substituted with K, phenyl disubstituted with K, 
phenyl trisubstituted with K, naphthyl, naphthyl substituted 
with K, naphthyl disubstituted with K, naphthyl trisubsti-
tuted with K, C1 _10 alkyl with an attached phenyl group, 
cl-10 alkyl with two attached phenyl groups, cl-10 alkyl 
with an attached phenyl group substituted with K, C1 _10 
alkyl with two attached phenyl groups substituted with K, 
cl-10 alkyl with an attached phenoxy group, and cl-10 alkyl 
with an attached phenoxy group substituted with K on the 
phenoxy group; 
J is selected from the group consisting of halogen, COOH, 
OH, CN, N02 , NH2 , C1 _10 alkoxy, C1 _10 alkylamine, C2 _12 
dialkylamine, C1 _10 alkyl-0-CO-, C1 _10 alkyl-0-
CO-NH-, and C1 _10 alkyl-S-; 
K is selected from the group consisting of halogen, C1 _10 
alkyl, C1 _10 perfiuoroalkyl, C1 _10 alkoxy, N02 , CN, OH, 
C02 H, amino, C1 _10 alkylamino, C2 _12 dialkylamino, 
C1-C10 acyl, and C1 _10 alkoxy-CO-, and C1 _10 alkyl-
S-; 
AA is a side chain blocked or unblocked amino acid with 
the L configuration, D configuration, or no chirality at the 
a-carbon selected from the group consisting of alanine, 
valine, leucine, isoleucine, praline, methionine, methionine 
sulfoxide, phenylalanine, tryptophan, glycine, serine, 
threonine, cysteine, tyrosine, asparagine, glutamine, aspartic 
acid, glutamic acid, lysine, arginine, histidine, 
phenylglycine, beta-alanine, norleucine, norvaline, alpha-
aminobutyric acid, epsilon-aminocaproic acid, citrulline, 
hydroxyproline, ornithine, homoarginine, sarcosine, indo-
line 2-carboxylic acid, 2-azetidinecarboxylic acid, pipe-DETAILED DESCRIPTION OF IBE 
INVENTION 
Peptide a-ketoamides are transition state analog inhibi-
tors for serine proteases and cysteine proteases. Peptide 
a-ketoamides containing hydrophobic amino acid residues 
in the P 1 site have been found to be excellent inhibitors of 
serine proteases including porcine pancreatic elastase and 
bovine chymotrypsin. We show that peptide a-ketoamides 
containing amino acid residues with cationic side chains in 
the P 1 site will be excellent inhibitors of several serine 
proteases including bovine trypsin, bovine thrombin, human 
plasma kallikrein, porcine pancreatic kallikrein, human fac-
tor Xia and human plasmin. Peptide a-ketoamides contain-
55 colinic acid (2-piperidine carboxylic acid), 0-methylserine, 
0-ethy lserine, S-methy lcysteine, S-ethy lcysteine, 
S-benzylcysteine, NH2-CH(CH2 CHEt2)-COOH, alpha-
aminoheptanoic acid, NH2-CH(CH2 -l-napthyl)-COOH, 
NH 2-CH(CH2 -2-napthyl)-COOH, NH 2 -CH(CH2 -
60 cyclohexyl)-COOH, NH 2-CH(CH2 -cyclopentyl)-
COOH, NH2-CH(CH2 -cyclobutyl)-COOH, NH2-CH 
(CH 2 -cyclopropyl)-COOH, trifiuoroleucine, and 
hexafiuoroleucine; 
R2 is selected from the group consisting of C1 _8 branched 
65 and unbranched alkyl, C1 _8 branched and unbranched 
cyclized alkyl, and C1 _8 branched and unbranched fiuoro-
alkyl; 
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R3 and R4 are selected independently from the group 
consisting of H, C1_20 alkyl, C3_20 cyclized alkyl, C1_20 alkyl 
with a phenyl group attached to the cl-20 alkyl, c3-20 
cyclized alkyl with an attached phenyl group, C1_20 alkyl 
with an attached phenyl group substituted with K, C1_20 
alkyl with an attached phenyl group disubstituted with K, 
C1_20 alkyl with an attached phenyl group trisubstituted with 
K, C3_20 cyclized alkyl with an attached phenyl group 
substituted with K, C1_10 alkyl with a morpholine [-N 
(CH2CH2)0] ring attached through nitrogen to the alkyl, 
C1_10 alkyl with a piperidine ring attached through nitrogen 
to the alkyl, C1_10 alkyl with a pyrrolidine ring attached 
through nitrogen to the alkyl, C1_20 alkyl with an OH group 
attached to the alkyl, -CH2CH20CH2CH20H, C1_10 with 
an attached 4-pyridyl group, C1_10 with an attached 
3-pyridyl group, cl-10 with an attached 2-pyridyl group, 
C1_10 with an attached cyclohexyl group, -NH-
CH2CH2-( 4-hydroxyphenyl), and -NH-CH2CH2-(3-
indolyl). 
The novel class of dipeptide a-ketoamides also have the 
following structural formula: 
or a pharmaceutically acceptable salt, wherein 
M1 represents H, NH2-CO-, NH2-CS-, NH2-
S02-, X-NH-CO-, X2N-CO-, X-NH-CS-, 
X2N-CS-, X-NH-S02-, X2N-S02-, X-CO-, 
X-CS-, X-502-, X-0-CO-, or X-0-CS-; 
X is selected from the group consisting of C1_10 alkyl, 
cl-10 fiuoroalkyl, cl-10 alkyl substituted with J, cl-10 fiuo-
roalkyl substituted with J, 1-admantyl, 9-fiuorenyl, phenyl, 
phenyl substituted with K, phenyl disubstituted with K, 
phenyl trisubstituted with K, naphthyl, naphthyl substituted 
with K, naphthyl disubstituted with K, naphthyl trisubsti-
tuted with K, C1_10 alkyl with an attached phenyl group, 
cl-10 alkyl with two attached phenyl groups, cl-10 alkyl 
with an attached phenyl group substituted with K, C1_10 
alkyl with two attached phenyl groups substituted with K, 
cl-10 alkyl with an attached phenoxy group, and cl-10 alkyl 
with an attached phenoxy group substituted with K on the 
phenoxy group; 
J is selected from the group consisting of halogen, COOH, 
OH, CN, N02, NH2, C1_10 alkoxy, C1_10 alkylamine, C2_12 
dialkylamine, C1_10 alkyl-0-CO-, C1_10 alkyl-0-
CO-NH-, and C1_10 alkyl-S-; 
K is selected from the group consisting of halogen, C1_10 
alkyl, C1_10 perfiuoroalkyl, C1_10 alkoxy, N02, CN, OH, 
C02H, amino, C1_10 alkylamino, C2_12 dialkylamino, 
CcC10 acyl, and C1_10 alkoxy-CO-, and C1_10 alkyl-
S-; 
8 
COOH, NH2-CH(CH2-cyclobutyl)-COOH, NH2-CH 
(CH2-cyclopropyl)-COOH, trifiuoroleucine, and 
hexafiuoroleucine; 
AA2 is a side chain blocked or unblocked amino acid with 
5 the L configuration, D configuration, or no chirality at the 
a-carbon selected from the group consisting of alanine, 
valine, leucine, isoleucine, praline, methionine, methionine 
sulfoxide, phenylalanine, tryptophan, glycine, serine, 
threonine, cysteine, tyrosine, asparagine, glutamine, aspartic 
10 acid, glutamic acid, lysine, arginine, histidine, 
phenylglycine, beta-alanine, norleucine, norvaline, alpha-
aminobutyric acid, epsilon-aminocaproic acid, citrulline, 
hydroxyproline, ornithine, homoarginine, sarcosine, indo-
line 2-carboxylic acid, 2-azetidinecarboxylic acid, pipe-
15 colinic acid (2-piperidine carboxylic acid), 0-methylserine, 
0-ethy lserine, S-methy lcysteine, S-ethy lcysteine, 
S-benzylcysteine, NH2-CH(CH2CHEt2)-COOH, alpha-
aminoheptanoic acid, NH2-CH(CH2-l-napthyl)-COOH, 
NH2-CH(CH2-2-napthyl)-COOH, NH2-CH(CH2-
20 cyclohexyl)-COOH, NH2-CH(CH2-cyclopentyl)-
COOH, NH2-CH(CH2-cyclobutyl)-COOH, NH2-CH 
(CH2-cyclopropyl)-COOH, trifiuoroleucine, and 
hexafiuoroleucine; 
R3 and R4 are selected independently from the group 
25 consisting of H, C1_20 alkyl, C3_20 cyclized alkyl, C1_20 alkyl 
with a phenyl group attached to the cl-20 alkyl, c3-20 
cyclized alkyl with an attached phenyl group, C1_20 alkyl 
with an attached phenyl group substituted with K, C1_20 
alkyl with an attached phenyl group disubstituted with K, 
30 C1_20 alkyl with an attached phenyl group trisubstituted with 
K, C3_20 cyclized alkyl with an attached phenyl group 
substituted with K, C1_10 alkyl with a morpholine [ -N 
(CH2CH2)0] ring attached through nitrogen to the alkyl, 
C1_10 alkyl with a piperidine ring attached through nitrogen 
35 to the alkyl, C1_10 alkyl with a pyrrolidine ring attached 
through nitrogen to the alkyl, C1_20 alkyl with an OH group 
attached to the alkyl, -CH2CH20CH2CH20H, C1_10 with 
an attached 4-pyridyl group, C1_10 with an attached 
3-pyridyl group, cl-10 with an attached 2-pyridyl group, 
40 C1_10 with an attached cyclohexyl group, -NH-CH2CH2-
( 4-hydroxyphenyl), and -NH-CH2CH2-(3-indolyl). 
45 
The novel class of tripeptide a-ketoamides have the 
following structural formula: 
or a pharmaceutically acceptable salt, wherein 
M1 represents H, NH2-CO-, NH2-CS-, NH2-
S02-, X-NH-CO-, X2N-CO-, X-NH-CS-, 
X2N-CS-, X-NH-S02-, X2N-S02-, X-CO-, 
50 X-CS-, X-502-, X-0-CO-, or X-0-CS-; 
AA1 is a side chain blocked or unblocked amino acid with 
the L configuration, D configuration, or no chirality at the 
a-carbon selected from the group consisting of alanine, 
valine, leucine, isoleucine, praline, methionine, methionine 
sulfoxide, phenylalanine, tryptophan, serine, threonine, 55 
cysteine, tyrosine, asparagine, glutamine, aspartic acid, 
glutamic acid, lysine, arginine, histidine, phenylglycine, 
beta-alanine, norleucine, norvaline, alpha-aminobutyric 
acid, epsilon-aminocaproic acid, citrulline, hydroxyproline, 
ornithine, homoarginine, sarcosine, indoline 2-carboxylic 60 
acid, 2-azetidinecarboxy lie acid, pipecolinic acid 
(2-piperidine carboxylic acid), 0-methylserine, 
0-ethy lserine, S-methy lcys teine, S-ethy lcysteine, 
S-benzylcysteine, NH2-CH(CH2CHEt2)-COOH, alpha-
aminoheptanoic acid, NH2-CH(CH2-l-napthyl)-COOH, 65 
NH2-CH(CH2-2-napthyl)-COOH, NH2-CH(CH2-
cyclohexy 1)-COOH, NH2-CH( CH2-cyclopenty 1)-
X is selected from the group consisting of C1_10 alkyl, 
cl-10 fiuoroalkyl, cl-10 alkyl substituted with J, cl-10 fiuo-
roalkyl substituted with J, 1-admantyl, 9-fiuorenyl, phenyl, 
phenyl substituted with K, phenyl disubstituted with K, 
phenyl trisubstituted with K, naphthyl, naphthyl substituted 
with K, naphthyl disubstituted with K, naphthyl trisubsti-
tuted with K, C1_10 alkyl with an attached phenyl group, 
cl-10 alkyl with two attached phenyl groups, cl-10 alkyl 
with an attached phenyl group substituted with K, C1_10 
alkyl with two attached phenyl groups substituted with K, 
cl-10 alkyl with an attached phenoxy group, and cl-10 alkyl 
with an attached phenoxy group substituted with K on the 
phenoxy group; 
J is selected from the group consisting of halogen, COOH, 
OH, CN, N02, NH2, C1_10 alkoxy, C1_10 alkylamine, C2_12 
dialkylamine, C-1_10 alkyl-0-CO-, C1_10 alkyl-0-
CO-NH-, and C1_10 alkyl-S-; 
US 6,235,929 Bl 
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dialkylamine, C1_10 alkyl-0-CO-, C1_10 alkyl-0-
CO-NH-, and C1_10 alkyl-S-; 
K is selected from the group consisting of halogen, C1_10 
alkyl, C1_10 perfiuoroalkyl, C1_10 alkoxy, N02, CN, OH, 
C02H, amino, C1_10 alkylamino, C2_12 dialkylamino, C1_10 
acyl, and C1_10 alkoxy-CO-, and C1_10 alkyl-S-; 
AA1, AA2, and AA3 are the same or different and are side 
chain blocked or unblocked amino acids with the L 
configuration, D configuration, or no chirality at the 
a-carbon selected from the group consisting of alanine, 
valine, leucine, isoleucine, praline, methionine, methionine 
sulfoxide, phenylalanine, tryptophan, glycine, serine, 10 
threonine, cysteine, tyrosine, asparagine, glutamine, aspartic 
acid, glutamic acid, lysine, arginine, histidine, 
phenylglycine, beta-alanine, norleucine, norvaline, alpha-
aminobutyric acid, epsilon-aminocaproic acid, citrulline, 
hydroxyproline, ornithine, homoarginine, sarcosine, indo- 15 
line 2-carboxylic acid, 2-azetidinecarboxylic acid, pipe-
colinic acid (2-piperidine carboxylic acid), 0-methylserine, 
0-ethy lserine, S-methy lcys teine, S-ethy lcysteine, 
S-benzylcysteine, NH2-CH(CH2CHEt2)-COOH, alpha-
aminoheptanoic acid, NH2-CH(CH2-l-napthyl)-COOH, 20 
NH2-CH(CH2-2-napthyl)-COOH, NH2-CH(CH2-
cyclohexyl)-COOH, NH2-CH(CH2-cyclopentyl)-
COOH, NH2-CH(CH2-cyclobutyl)-COOH, NH2-CH 
(CH2-cyclopropyl)-COOH, trifiuoroleucine, and 
hexafiuoroleucine; 
K is selected from the group consisting of halogen, C1_10 
alkyl, C1_10 perfiuoroalkyl, C1_10 alkoxy, N02, CN, OH, 
5 C02H, amino, C1_10 alkylamino, C2_12 dialkylamino, 
C1-C10 acyl, and C1_10 alkoxy-CO-, and C1_10 alkyl-
S-· 
AA1, AA2, and AA3 are the same or different and are side 
chain blocked or unblocked amino acids with the L 
configuration, D configuration, or no chirality at the 
a-carbon selected from the group consisting of alanine, 
valine, leucine, isoleucine, praline, methionine, methionine 
sulfoxide, phenylalanine, tryptophan, glycine, serine, 
threonine, cysteine, tyrosine, asparagine, glutamine, aspartic 
acid, glutamic acid, lysine, arginine, histidine, 
phenylglycine, beta-alanine, norleucine, norvaline, alpha-
aminobutyric acid, epsilon-aminocaproic acid, citrulline, 
hydroxyproline, ornithine, homoarginine, sarcosine, indo-
line 2-carboxylic acid, 2-azetidinecarboxylic acid, pipe-
colinic acid (2-piperidine carboxylic acid), 0-methylserine, 
0-ethy lserine, S-methy lcysteine, S-ethy lcysteine, 
S-benzylcysteine, NH2-CH(CH2CHEt2)-COOH, alpha-
aminoheptanoic acid, NH2-CH(CH2-l-napthyl)-COOH, 
NH2-CH(CH2-2-napthyl)-COOH, NH2-CH(CH2-
cyclohexyl)-COOH, NH2-CH(CH2-cyclopentyl)-
25 COOH, NH2-CH(CH2-cyclobutyl)-OOH, NH2-CH 
(CH2-cyclopropyl)-COOH, trifiuoroleucine, and 
hexafiuoroleucine; 
R3 and R4 are selected independently from the group 
consisting of H, C1_20 alkyl, C3_20 cyclized alkyl, C1_20 alkyl 
with a phenyl group attached to the cl-20 alkyl, c3-20 
cyclized alkyl with an attached phenyl group, C1_20 alkyl 
with an attached phenyl group substituted with K, C1_20 30 
alkyl with an attached phenyl group disubstituted with K, 
C1_20 alkyl with an attached phenyl group trisubstituted with 
K, C3_20 cyclized alkyl with an attached phenyl group 
substituted with K, C1_10 alkyl with a morpholine [-N 
(CH2CH2)0] ring attached through nitrogen to the alkyl, 35 
C1_10 alkyl with a piperidine ring attached through nitrogen 
to the alkyl, C1_10 alkyl with a pyrrolidine ring attached 
through nitrogen to the alkyl, C1_20 alkyl with an OH group 
attached to the alkyl, -CH2CH20CH2CH20H, C1_10 with 
an attached 4-pyridyl group, C1_10 with an attached 40 
3-pyridyl group, cl-10 with an attached 2-pyridyl group, 
C1_10 with an attached cyclohexyl group, -NH-CH2CH2-
( 4-hydroxyphenyl), and -NH-CH2CH2-(3-indolyl). 
R3 and R4 are selected independently from the group 
consisting of H, C1_20 alkyl, C3_20 cyclized alkyl, C1_20 alkyl 
with a phenyl group attached to the cl-20 alkyl, c3-20 
cyclized alkyl with an attached phenyl group, C1_20 alkyl 
with an attached phenyl group substituted with K, C1_20 
alkyl with an attached phenyl group disubstituted with K, 
C1_20 alkyl with an attached phenyl group trisubstituted with 
K, C3_20 cyclized alkyl with an attached phenyl group 
substituted with K, C1_10 alkyl with a morpholine [ -N 
(CH2CH2)0] ring attached through nitrogen to the alkyl, 
C1_10 alkyl with a piperidine ring attached through nitrogen 
to the alkyl, C1_10 alkyl with a pyrrolidine ring attached 
through nitrogen to the alkyl, C1_20 alkyl with an OH group 
attached to the alkyl, -CH2CH20CH2CH20H, C1_10 with 
an attached 4-pyridyl group, C1_10 with an attached 
3-pyridyl group, cl-10 with an attached 2-pyridyl group, 
C1_10 with an attached cyclohexyl group, -NH-CH2CH2-The novel class of tetrapeptide a-ketoamides have the following structural formula: 45 (4-hydroxyphenyl), and -NH-CH2CH2-(3-indolyl). 
or a pharmaceutically acceptable salt, wherein 
M1 represents H, NH2-CO-, NH2-CS-, NH2-
S02-, X-NH-CO-, X2N-CO-, X-NH-CS-, 50 
X2N-CS-, X-NH-S02-, X2N-S02-, X-CO-, 
X-CS-, X-502-, X-0-CO-, or X-0-CS-; 
The novel class of amino acid a-ketoamides have the 
following structural formula: 
or a pharmaceutically acceptable salt, wherein 
M1 represents H, NH2-CO-, NH2-CS-, NH2-
S02-, X-NH-CO-, X2N-CO-, X-NH-CS-, 
X2N-CS-, X-NH-S02-, X2N-S02-, X-CO-, 
X-CS-, X-502-, X-0-CO-, or X-0-CS-; 
X is selected from the group consisting of C1_10 alkyl, 
cl-10 fiuoroalkyl, cl-10 alkyl substituted with J, cl-10 fiuo-
roalkyl substituted with J, 1-admantyl, 9-fiuorenyl, phenyl, 
phenyl substituted with K, phenyl disubstituted with K, 
phenyl trisubstituted with K, naphthyl, naphthyl substituted 
with K, naphthyl disubstituted with K, naphthyl trisubsti-
tuted with K, C1_10 alkyl with an attached phenyl group, 
cl-10 alkyl with two attached phenyl groups, cl-10 alkyl 
with an attached phenyl group substituted with K, C1_10 
alkyl with two attached phenyl groups substituted with K, 
X is selected from the group consisting of C1_10 alkyl, 
cl-10 fiuoroalkyl, cl-10 alkyl substituted with J, cl-10 fiuo-
roalkyl substituted with J, 1-admantyl, 9-fiuorenyl, phenyl, 55 
phenyl substituted with K, phenyl disubstituted with K, 
phenyl trisubstituted with K, naphthyl, naphthyl substituted 
with K, naphthyl disubstituted with K, naphthyl trisubsti-
tuted with K, C1_10 alkyl with an attached phenyl group, 
cl-10 alkyl with two attached phenyl groups, cl-10 alkyl 60 
with an attached phenyl group substituted with K, C1_10 
alkyl with two attached phenyl groups substituted with K, 
cl-10 alkyl with an attached phenoxy group, and cl-10 alkyl 
with an attached phenoxy group substituted with K on the 
phenoxy group; 65 cl-10 alkyl with an attached phenoxy group, and cl-10 alkyl 
with an attached phenoxy group substituted with K on the 
phenoxy group; 
J is selected from the group consisting of halogen, COOH, 
OH, CN, N02, NH2, C1_10 alkoxy, C1_10 alkylamine, C2_12 
US 6,235,929 Bl 
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J is selected from the group consisting of halogen, COOH, 
OH, CN, N02 , NH2 , C1 _10 alkoxy, C1 _10 alkylamine, C2 _12 
dialkylamine, C1 _10 alkyl-0-CO-, C1 _10 alkyl-0-
CO-NH-, and C1 _10 alkyl-S-; 
12 
Z-Leu-Abu-CONH---( CH2) 2 0( CH2) 2 0H 
Z-Leu-Abu-CONH---( CH2) 17CH3 
Z-Leu-Abu-CONH-CH2-C6HiOCH3) 2 
Z-Leu-Abu-CONH-CH2-C4 H4 N 
Materials and Methods 
HEPES, heparin, and A23187 were obtained from Cal-
biochem. Suc-Leu-Tyr-AMC and chromogenic sub-
strates were obtained from Sigma Calpain I was purified 
from human erythrocytes according to the method of 
K is selected from the group consisting of halogen, C1 _10 
5 
alkyl, C1 _10 perfiuoroalkyl, C1 _10 alkoxy, N02 , CN, OH, 
C02 H, amino, C1 _10 alkylamino, C2 _12 dialkylamino, 
CcC10 acyl, and C1 _10 alkoxy-CO-, and C1 _10 alkyl-
S-; 10 Kitahara (Kitahara et al., J. Biochem. 95, 1759-1766) omit-
ting the Blue-Sepharose step. Calpain II from rabbit muscle 
and cathepsin B were purchased from Sigma. Papain was 
purchased from Calbiochem. 
Assay of Inhibitory Potency 
Peptide a-ketoamides were assayed as reversible enzyme 
inhibitors. Various concentrations of inhibitors in Me2SO 
were added to the assay mixture which contained buffer and 
substrate. The reaction was started by the addition of the 
enzyme and the hydrolysis rates were followed spectropho-
20 tometrically or fiuorimetrically. 
AA is a side chain blocked or unblocked amino acid with 
the L configuration, D configuration, or no chirality at the 
a-carbon selected from the group consisting of alanine, 
valine, leucine, isoleucine, praline, methionine, methionine 
sulfoxide, phenylalanine, tryptophan, glycine, serine, 15 
threonine, cysteine, tyrosine, asparagine, glutamine, aspartic 
acid, glutamic acid, lysine, arginine, histidine, 
phenylglycine, beta-alanine, norleucine, norvaline, alpha-
aminobutyric acid, epsilon-aminocaproic acid, citrulline, 
hydroxyproline, ornithine, homoarginine, sarcosine, indo-
line 2-carboxylic acid, 2-azetidinecarboxylic acid, pipe-
colinic acid (2-piperidine carboxylic acid), 0-methylserine, 
0-ethy lserine, S-methy lcys teine, S-ethy lcysteine, 
S-benzylcysteine, NH2-CH(CH2 CHEt2)-COOH, alpha-
aminoheptanoic acid, NH2-CH(CH2 -l-napthyl)-COOH, 
NH 2-CH(CH2 -2-napthyl)-COOH, NH2 -CH(CH2 -
cyclohexyl)-COOH, NH 2-CH(CH2 -cyclopentyl)-
COOH, NH2-CH(CH2 -cyclobutyl)-COOH, NH2-CH 
(CH 2 -cyclopropyl)-COOH, trifiuoroleucine, and 
hexafiuoroleucine; 
Calpain I from human erythrocytes and calpain II from 
rabbit were assayed using Suc-Leu-Tyr-AMC [Sasaki et al., 
J. Biol. Chem. 259, 12489-12494 (1984); incorporated 
herein by reference], and the AMC (7-amino-4-
25 methylcoumarin) release was followed fiuorimetrically 
(excitation at 380 nm, and emmision at 460 nm). Calpains 
were assayed in 25 mM Tris pH=8.0, 10 mM CaC12 . 
Fluorescence was followed using a Gilson FL-lA fiuorom-
eter or a Perkin-Elmer 203 Fluorescence spectrometer. 
30 Cathepsin B was assayed in 20 mM sodium acetate pH=5.2, 
0.5 mM dithiothreitol using Bz-Phe-Val-Arg-p-nitroanilide 
as substrate. Alternately, cathepsin B was assayed with 
Z-Arg-Arg-AFC [Barrett and Kirschke, Methods Enzymol. 
80, 535-561 (1981); incorporated herein by reference], and 
R3 and R4 are selected independently from the group 
consisting of H, C1 _20 alkyl, C3 _20 cyclized alkyl, C1 _20 alkyl 
with a phenyl group attached to the cl-20 alkyl, c3-20 
cyclized alkyl with an attached phenyl group, C1 _20 alkyl 
with an attached phenyl group substituted with K, C1 _20 
alkyl with an attached phenyl group disubstitured with K, 
C1 _20 alkyl with an attached phenyl group trisubstituted with 
K, C3 _20 cyclized alkyl with an attached phenyl group 
substituted with K, C1 _10 alkyl with a morpholine [-N 
(CH2 CH2)0] ring attached through nitrogen to the alkyl, 
C 1 _10 alkyl with a piperidine ring attached through nitrogen 
to the alkyl, C1 _10 alkyl with a pyrrolidine ring attached 
through nitrogen to the alkyl, C1 _20 alkyl with an OH group 
attached to the alkyl, -CH2 CH2 0CH2 CH2 0H, C1 _10 with 
an attached 4-pyridyl group, C1 _10 with an attached 
3-pyridyl group, C 1 _10 with an attached 2-pyridyl group, 
C1 _10 with an attached cyclohexyl group, -NH-CH2 CH2 -
( 4-hydroxyphenyl), and -NH-CH2 CH2 -(3-indolyl). 
The following compounds are representatives of the 
invention: 
Z-Leu-Phe-CONH-Et 
Z-Leu-Phe-CONH-nPr 
Z-Leu-Phe-CONH-nBu 
Z-Leu-Phe-CONH-iBu 
Z-Leu-Phe-CONH-Bzl 
Z-Leu-Phe-CONH---(CH2 ) 2 Ph 
Z-Leu-Abu-CONH-Et 
Z-Leu-Abu-CONH-nPr 
Z-Leu-Abu-CONH-nBu 
Z-Leu-Abu-CONH-iBu 
Z-Leu-Abu-CONH-Bzl 
Z-Leu-Abu-CONH---( CH2) 2Ph 
Z-Leu-Abu-CONH---(CH2h-N(CH2 CH2) 2 0 
Z-Leu-Abu-CONH---( CH2hCH3 
Z-Leu-Abu-CONH---(CH2) 2 0H 
35 the AFC (7-amino-4-trifiuoromethylcoumarin) release was 
followed fiuorimetrically (excitation at 400 nm and emmi-
sion at 505 nm). Papain was assayed in 100 mM KP04 , 1 
mM EDTA, 2.5 mM cysteine pH=6.0 using Bz-Arg-AMC or 
Bz-Arg-NA [Kanaoka et al., Chem. Pharm. Bull. 25, 
40 3126-3128 (1977); incorporated herein by reference] as a 
substrate. The AMC (7-amino-4-methylcoumarin) release 
was followed fiuorimetrically (excitation at 380 nm, and 
emmision at 460 nm). Enzymatic hydrolysis rates were 
measured at various substrate and inhibitor concentrations, 
45 and KI values were determined by either Lineweaver-Burk 
plots or Dixon plots. 
A 0.1 M Hepes, 0.5 M NaCl, pH 7.5 buffer was utilized 
for human leukocyte elastase (HLE), porcine pancreatic 
elastase (PPE), chymotrypsin and cathepsin G. A 0.1 Hepes, 
50 0.01 M CaC12 , pH 7.5 buffer was utilized for trypsin, 
plasmin, and coagulation enzymes. A 50 mM Tris-HCl, 2 
mM EDTA, 5 mM cysteine, pH 7.5 was used as a buffer for 
papain. A 88 mM KH2P04, 12 mM Na2 HP04 , 1.33 mM 
EDTA, 2.7 mM cysteine, pH 6.0 solution was used as a 
55 buffer for cathepsin B. A 20 mM Hepes, 10 mM CaC12 , 10 
mM mercatoethanol, pH 7.2 buffer was utilized for calpain 
I and calpain II. 
HLE and PPE were assayed with MeO-Suc-Ala-
Ala-Pro-Val-NA and Sue-Ala-Ala-Ala-NA, 
60 respectively [Nakajima et al., J. Biol. Chem. 254, 
4027-4032 (1979); incorporated herein by reference]. 
Human leukocyte cathepsin G and chymotrypsin A,, were 
assayed with Suc-Val-Pro-Phe-NA [Tanaka et al., Biochem-
istry 24, 2040-204 7 (1985); incorporated herein by 
65 reference]. The hydrolysis of peptide 4-nitroanilides was 
measured at 410 nm [E410=8800 M-1 cm-1; Erlanger et al., 
Arch. Biochem. Biophys. 95, pp 271-278 (1961); incorpo-
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side chains (e.g. Z-Leu-Abu-CONH---(CH2hCH3), 
alkyl side chains with phenyl substituted on the alkyl group 
(e.g. Z-Leu-Abu-CONH-(CH2)2-Ph), or alkyl 
groups with a morpholine ring substituted on the alkyl group 
rated herein by reference]. Trypsin, thrombin, human plasma 
kallikrein, porcine pancreatic kallikrein, human factor Xia, 
and human plasmin were assayed with Z-Arg-SBzl or 
Z-Gly-Arg-SBu-i [McRae et al., Biochemistry 20, 
7196-7206 (1981); incorporated herein by reference]. All 
peptide thioester hydrolysis rates were measured with assay 
mixtures containing 4,4'-dithiodipyridine [E324=19800 M-1 
cm-1 ; Grasetti & Murray, Arch. Biochem. Biophys. 119, 
41-49 (1967); incorporated herein by reference]. 
5 [e.g. Z-Leu-Abu-CONH-(CH2)3-Mpl, Mpl=-N 
(CH2CH2)20]. Dipeptide a-ketoamides with a small ali-
phatic amino acid residue or a Phe in the P 1 site are also 
good inhibitors for cathepsin B. The best inhibitor is 
Z-Leu-Abu-CONH-Et and replacement of the Z 
10 (PhCH20CO-) by PhCH2CH2CO-, PhCH2CH2S02-, 
PhCH2NHCO-, and PhCH2NHCS- would also result in 
good inhibitor structures. 
Platelet membrane permeability assay. Calpain-mediated 
breakdown of spectrin was measured by quantitative densi-
tometry of the calpain-specific 150/155 kDa spectrin frag-
ment doublet [see Siman et al., Proc. Natl. Acad. Sci USA 
81, 3572-3576 (1984)]. Platelets were isolated by a modi-
fication of the method of Ferrell and Martin [J. Biol. Chem. 15 
264, 20723-20729 (1989)]. Blood (15-20 ml) was drawn 
from male Sprague-Dawley rats into 1/lOth volume of 100 
mM EDTA-citrate, and centrifuged 10 minutes at 2000 rpm 
TABLE I 
Inhibition of Cysteine Proteases by Peptide a-Ketoamides. 
in a clinical centrifuge at room temperature. The plasma was 
resuspended in 15 ml of buffer 1 (136 mM NaCl, 2.7 mM 
KCl, 0.42 mM NaH2P04, 12 mM NaHC03, 2 mM MgCl2, 
2 mg/ml BSA (Sigma), 5.6 mM glucose, 22 mM Na3citrate 
pH 6.5) and platelets were isolated at 2200 rpm at room 
temperature for 10 minutes. Platelets were washed once in 
20 Peptide a-Ketoamide Calpain I 
Cal pain 
II Cath B 
Z-Leu-Abu-CONH-Et 
Z-Leu-Abu-CONH-nPr 
Z-Leu-Abu-CONH-nBu 
Z-Leu-Abu-CONH-iBu 
Z-Leu-Abu-CONH-Bzl 
Z-Leu-Abu-CONH-(CH2)o-Ph 
Z-Leu-Abu-CONH-(CH2) 3-Mpl 
Z-Leu-Abu-CONH-(CHo) 7CH3 
Z-Leu-Abu-CONH-(CH2) 17CH3 
Z-Leu-Abu-CONH-(CH2) 20H 
0.5 
0.2 
0.23 
0.25 
0.14 
0.35 
0.022 
0.041 
0.019 
0.078 
2.4 
8 
13 
4 
2 15 ml buffer 1, then resuspended to 107 cells/ml in buffer 2 25 
(136 mM NaCl, 2.7 mM KCl, 0.42 mM NaH2P04, 12 mM 
NaHC03, 2 mM MgCl, 1 mg/ml BSA (Sigma), 5.6 mM 
glucose, 20 mM HEPES (Sigma) pH 7.4) and allowed to 
"rest" for a minimum of 10 minutes at room temperature 
before use. 30 Z-Leu-Abu-CONH-(CH2) 20(CH2) 20H 
Z-Leu-Phe-CONH-Et Inhibitors were added from stock solutions made fresh in 
DMSO. 100 µl platelets, suspended to 107 cells/ml in buffer 
0.16 
7.0 0.32 
0.05 
0.028 
0.065 
0.046 
0.024 
Z-Leu-Phe-CONH-nPr 
Z-Leu-Phe-CONH-nBu 
Z-Leu-Phe-CONH-iBu 
Z-Leu-Phe-CONH-Bzl 
15.0 3 
3 
4 2, were incubated with 1 µl of an inhibitor solution for 5 
minutes at room temperature prior to the addition of 2 mM 
Ca2+ and 1 µM A23187. After 10 minutes total exposure to 
inhibitor (5 minutes exposure to ionophore) at room 
temperature, platelets were reisolated at 14,000 rpm for 10 
sec in a Beckman microfuge, dissolved in SDS-PAGE 
sample buffer, and heated to 90° C. for 3 minutes. 
35 
Z-Leu-Phe-CONH(CH2 ) 2 Ph 
Samples were subjected to SDS-PAGE in 4-12% gradient 40 
mini gels (Novex) and transferred to nitrocellulose 
(Schleicher and Schnell 0.45 um) by electroblotting. Filters 
were blocked for 10 minutes in 0.25% gelatin, 1 % BSA, 
0.25% triton XlOO, 0.9% NaCl, 10 mM Tris-Cl pH 7.5, 
incubated overnight in the same solution containing anti- 45 
body to rat spectrin, washed 3x10 minutes with 10 mM 
Tris-Cl pH 7.5, 0.5% triton X 100, incubated 4 hours in wash 
buffer plus alkaline phosphatase conjugated goat anti-rabbit 
antibody (Biorad), and washed as above. Blots were devel-
oped using the Biorad AP conjugate substrate kit. Quanti- 50 
tative densitometry was used to obtain values for the intact 
spectrin bands and the 150/155 kDa breakdown product 
doublet. 
Structure-Activity Relationships 
Table II shows the inhibition constants (KI) for PP elastase 
and chymotrypsin. Dipeptide a-ketoamides with Abu in the 
P 1 site are potent inhibitors of PP elastase. The structures 
with medium sized straight-chain alkyl groups such as n-Pr 
and n-Bu were better inhibitors than a small alkyl (Et) or a 
branched alkyl (i-Bu). Dipeptide a-ketoamides with Phe in 
the P 1 site are moderate inhibitors of chymotrypsin. The 
inhibitor with R3=n-Bu and R4=H was the best in the series. 
In general the inhibitors were more potent at inhibiting 
cysteine protease than serine proteases. Extending the pep-
tide chain to tripeptide or tetrapeptide a-ketoamides would 
improve the inhibitory potency toward serine proteases. 
TABLE II 
Inhibition of Serine Proteases by Peptide a-Ketoamides. 
Table I shows the inhibition constants (KI) for cathepsin 55 Peptide a-Ketoamide Chymotrypsin PP elastase 
B, calpain I, and calpain II. Dipeptide a-ketoamides with 
Abu and Phe in the P 1 site and Leu in the P 2 site are potent 
inhibitors of calpain I and calpain II. Z-Leu-Abu-
CONH-Et is a better inhibitor of calpain I than Z-Leu-
Phe-CONH-Et by 14 fold. Replacement of the Z group 60 
(PhCH 20CO-) by similar groups such as 
PhCH2CH2CO-, PhCH2CH2S02-, PhCH2NHCO-, and 
PhCH2NHCS- would also result in good inhibitor struc-
tures. The best inhibitor of calpain II is Z-Leu-Abu-
CONH-(CH2)2-Ph. Changing the R3 and R4 groups sig- 65 
nificantly improves the inhibitory potency toward calpain II. 
The best dipeptide inhibitors are those which have long alkyl 
Z-Leu-Abu-CONH-Et 
Z-Leu-Abu-CONH-nPr 
Z-Leu-Abu-CONH-nBu 
Z-Leu-Abu-CONH-iBu 
Z-Leu-Abu-CONH-Bzl 
Z-Leu-Abu-CONH-(CHo)2-Ph 
Z-Leu-Abu-CONH-(CH2) 3-Mpl 
Z-Leu-Abu-CONH-(CH2) 7CH3 
Z-Leu-Abu-CONH-(CH2) 17CH3 
Z-Leu-Abu-CONH-(CHo)20H 
Z-Leu-Abu-CONH-(CH2) 20(CH2) 20H 
Z-Leu-Phe-CONH-Et 
Z-Leu-Phe-CONH-nPr 
>150 
>300 
>300 
>300 
>300 
73 
18 
65 
2 
5 
40 
>150 
>300 
US 6,235,929 Bl 
15 
TABLE II-continued 
Inhibition of Serine Proteases by Peptide a-Ketoamides. 
Peptide a-Ketoamide 
Z-Leu-Phe-CONH-nBu 
Z-Leu-Phe-CONH-iBu 
Z-Leu-Phe-CONH-Bzl 
Z-Leu-Phe-CONH(CH2 ) 2Ph 
Chymotrypsin PP elastase 
8 >100 
24 
5 
10 
Peptide a-ketoamide were substantially more stable in 
both plasma and liver than the corresponding peptide 
a-ketoesters (Table III). The peptide a-ketoamides were 15 
also much more effective in the platelet assay. Extending the 
R3 group to an alkyl group or an alkyl group substituted with 
a phenyl group increased the membrane permeability of the 
inhibitors as indicated by increased potency in the platelet 
20 
assay. 
TABLE III 
Half-lives in Plasma and in Liver and Activity in the Platelet Assay. 
25 
ti12 ti12 
Peptide a-Ketoamide or Ester platelet plasma liver 
Z-Leu-Abu-COOEt 42 2.8 
Z-Leu-Abu-COOn-Bu 28 
Z-Leu-Abu-COOBzl ++ 30 
Z-Leu-Leu-Abu-COOEt 40 
2-NapS02-Leu-Leu-Abu-COOEt 100 >60 
2-NapCO-Leu-Leu-Abu-COO Et 25 
Tos-Leu-Leu-Abu-COOEt 30 30 
Z-Leu-Abu-COOH 8 >60 >60 
Z-Leu-Abu-CONH-Et 1.5 >60 >60 
Z-Leu-Abu-CONH-nPr 70 >60 >60 35 
Z-Leu-Abu-CONH-nBu 2.0 >60 >60 
Z-Leu-Abu-CONH-iBu 28 >60 
Z-Leu-Abu-CONH-Bzl 1.5 >60 >60 
Z-Leu-Phe-COOEt 42 7.8 
Z-Leu-Phe-COOnBu +++ 7.7 
Z-Leu-Phe-COOBz ++ 1.9 40 
16 
TABLE III-continued 
Half-lives in Plasma and in Liver and Activity in the Platelet Assay. 
tv2 tv2 
Peptide a-Ketoamide or Ester platelet plasma liver 
Z-Leu-Leu-Phe-COOEt ++ 
Z-Leu-Phe-COOH 6.5 >60 >60 
Z-Leu-Phe-CONH-Et 1.7 >60 >60 
Z-Leu-Phe-CONH-nPr 24 >60 >60 
Z-Leu-Phe-CONH-nBu 38 >60 >60 
Z-Leu-Phe-CONH-iBu 22 >60 
Z-Leu-Phe-CONH-Bzl 
Z-Leu-Phe-CONH(CH2 ) 2Ph 3.0 >60 
Z-Leu-Nle-COOEt 20 3.7 
Z-Leu-Nva-COOEt 40 2.8 
Z-Leu-Met-COOEt + 8 
(+++=excellent activity; ++=good activity, +=moderate 
activity; quantitiative measurements not yet complete) 
Inhibition Mechanism 
A crystal structure of one a-ketoester bound into the 
active site of porcine pancreatic elastase has been completed 
and a schematic drawing of the interactions observed is 
shown below. The active site Ser-195 oxygen of the enzyme 
has added to the carbonyl group of the ketoester to form a 
tetrahedral intermediate which is stabilized by interactions 
with the oxyanion hole. This structure resembles the tetra-
hedral intermediate involved in peptide bond hydrolysis and 
proves that a-ketoesters are transition-state analogs. His-57 
is hydrogen bonded to the carbonyl group of the ester 
functional group, the peptide backbone on a section of PPE's 
backbone hydrogen bonds to the inhibitor to form a ~-sheet, 
and the benzyl ester is directed toward the S' subsites. The 
side chain of the P 1 amino acid residue is located in the S1 
pocket of the enzyme. Interactions with ketoamides would 
be similar except for that there would be the possibility of 
forming an additional hydrogen bond with the NH group of 
the ketoamide functional group if R3 or R4 was H. If R3 
and/or R4 are longer substutuents, then they would make 
favorable interactions with the S' subsites of the enzyme. 
S1 ITT Ser-195 ~ 
QO ~,1-tKO~ Y T I _.O;:- o\ 
S' subsites 
9 I,I ,. ', Ii 
, oxyanion \ 
I TI hole N~ _,,Nnr,~ ~N'" 
Val-216 o Ser-214 
His-57 
Phe-214 
60 
65 
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The active site of cysteine proteases share several features 
in common with serine proteases including an active site 
histidine residue. In place of the Ser-195, cysteine proteases 
have an active site cysteine residue which would add to the 
ketonic carbonyl group of the peptide keto acids, keto esters, 5 
or ketoamides to form an adduct very similar to the structure 
depicted above except with a cysteine residue replacing the 
serine-195 residue. Additional interactions would occur 
18 
Z-Gl y-Leu-Phe-CO-NR3R4 
Me0-Suc-Ala-Ala-Pro-Met-CO-NR3R4 
Boc-Ala-Ala-Asp-CO-NR3R4 
Suc-Pro-Leu-Phe-CO-NR3R4 and 
Boc-Ala-Ala-Phe-CO-NR3R4 
Boc-Gly-Leu-Phe-CO-NR3R4, 
Suc-Phe-Leu-Phe-CO-NR3R4 between the extended substrate binding site of the cysteine 
protease and the inhibitor which would increase the binding 
affinity and specificity of the inhibitors. 
10 Boc-Ala-Ala-Glu-CO-NR3R4 
Z-Gl y-Gly-Pro-CO-NR3R4 
Inhibitor Design and Selection 
Ala-Pro-CO-NR3R4 
Sue-Ala-Ala-Pro-Val-CO-NR3R4 
Suc-Lys(Cbz)-Val-Pro-Val-CO-NR3R4, The peptide and amino acid a-ketoamide derivatives, as 
shown in the above crystal structure, bind to the enzymes 
using many of the interactions that are found in complexes 
of a particular individual enzyme with its substrates. In order 
to design an inhibitor for a particular serine or cysteine 
protease, it is necessary to: 1) find the amino acid sequences 
15 adamantyl-SOo-Lys(COCH2CH2C02H)-
Ala-Val-CO-NR3R4, adamantyl-
CH2CH20CO-Glu(O-t-Bu)-Pro-Val-
CO-NR3R4, and adamantyl-S02-
Lys(CO---C6H4C02H)-Ala-Val-
CO-NR3R4 
20 
Suc-Ala-Ala-Pro-Leu-CO-NR3R4 
of good peptide substrates for that enzyme, and 2) place 
those or similar amino acid sequences into a a-ketoamide 
structure. Additional interactions with the enzyme can be 
obtained by tailoring the R group of the inhibitor to imitate 
25 
the amino acid residues which are preferred by an individual 
protease at the S1 ' and S2' subsites. For example, ketoesters 
with R3 and/or R4=branched alkyl groups would interact 
effectively with serine and cysteine proteases which prefer 
Leu, Ile, and Val residues at P 1 ' and/or P 2', while amides with 30 
R=alkyl substituted with phenyl would interact effectively 
with serine and cysteine proteases which prefer Phe, Tyr, Trp 
residues at P1 ' and/or P2'. Likewise, the M1 group can be 
tailored to interact with the S subsites of the enzyme. This 
design strategy will also work when other classes of peptide 35 
inhibitors are used in place of the peptide substrate to gain 
information on the appropriate sequence to place in the 
ketoester, ketoacid, or ketoamide inhibitor. Thus, we are able 
Glu-Phe-Lys-CO-NR3R4 and 
Dns-Ala-Phe-Lys-CO-NR3R4 
D-Val-Gly-Arg-CO-NR3R4 and 
Dns-Glu-Gly-Arg-CO-NR3R4 
Z-Phe-Arg-CO-NR3R4 and 
Z-Trp-Arg-CO-NR3R4 
Z-Lys-Arg-CO-NR3R4 
Z-Gly-Arg-CO-NR3R4 
Z-Ile-Ala-Gly-Arg-CO-NR3R4 
Glu-Gly-Arg-CO-NR3R4 
Dns-Phe-Pro-Arg-CO-NR3R4 
Dns-Ile-Pro-Arg-CO-NR3R4 
Z-Trp-Arg-CO-NR3R4 
Z-Gly-Arg-CO-NR3R4 
Z-Phe-Arg-CO-NR3R4 
Dns-Glu-Gly-Arg-CO-NR3R4 
D-Phe-Pro-Arg-CO-NR3R4, 
D-MePhe-Pro-Arg-CO-NR3R4, and 
Boc-D-Phe-Pro-Arg-CO-NR3R4 
Z-Phe-Gly-Arg-CO-NR3R4 
Cl-C6H4CH20CO-Phe-Gly-CO-NR3R4 
C6H5 CH2NHCO-Gly-Phe-Gly-
CO-NR3R4 
for cathepsin G and RMCP II 
for cathepsin G 
for human lymphocyte 
granzyme B 
for RMCP I (RMCP ~ rat 
mast cell protease) 
for human and dog skin 
chymase 
for S. aureus V-8 protease 
for human prolyl 
endopeptidase 
for OPP IV 
for PPE 
for human leukocyte 
(neutrophil) elastase 
for elastolytic proteinase from 
"Schistosoma mansoni" 
for plasmin 
for factor Xa 
for porcine pancreatic and 
human plasma kallikreins 
for human skin tryptase 
for human lung tryptase 
for factors !Xa, Xa, Xia, Xlla 
and bovine plasma kallikrein 
for urokinase 
for plasminogen activator 
for activated protein C 
for bovine factor !Xa 
for bovine factor Xa and Xia 
for bovine factor Xlla 
for human factor Xa 
for human thrombin 
for trypsin 
for papain 
for cathepsin B 
to predict the structure of new inhibitors for other serine and 
cysteine proteases based on knowledge of their substrate 40 
specificities. Once a good inhibitor structure for a particular 
enzyme is found, it is then possible to change other char-
acteristics such as solubility or hydrophobicity by adding 
substituents to the M1 or R3 and R4 groups. 
R3 and R4 are selected independently from the group 
consisting of H, C1 _20 alkyl, C3_20 cyclized alkyl, C1 _20 alkyl 
with a phenyl group attached to the cl-20 alkyl, c3-20 
Elastase is an enzyme which hydrolyzes most effectively 
tetra- and tripeptides having P 1 residues with small alkyl 
side chains such as Ala and Val. MeO-Suc-Ala-Ala-
Ala-Val-NA and Z-Ala-Ala-Ala-Ala-NA are 
good substrates (NA=4-nitroanilide). Thus the correspond-
ing a-ketoamide Z-Ala-Ala-Ala-DL-Ala-CO-
NR3R4 and Me0-Suc-Ala-Ala-Pro-DL-Abu-
CO-NR3R4 will be excellent elastase inhibitors. Suc-
Phe-Leu-Phe-N A is an excellent substrate for 
chymotrypsin, cathepsin G, and mast cell chymases. Thus, 
the corresponding a-ketoamide will be an excellent inhibitor 
for these chymotrypsin-like enzymes. In the case of the 
cysteine protease calpain, a good inhibitor sequence is 
Ac-leu-Leu-Nle-H. We have found that ketoesters 
related in structure such as Z-Leu-Abu-CO-NR3R4 
and Z-Leu-Phe-CO-NR3R4 are potent inhibitors for 
cal pain. 
The following structures are predicted to be potent inhibi-
tors for the listed enzymes. The inhibitor sequences were 
obtained from peptide substrate and/or inhibitor sequences 
in the protease literature. 
45 cyclized alkyl with an attached phenyl group, C1 _20 alkyl 
with an attached phenyl group substituted with K, C1 _20 
alkyl with an attached phenyl group disubstituted with K, 
C1 _20 alkyl with an attached phenyl group trisubstituted with 
K, C3_20 cyclized alkyl with an attached phenyl group 
50 substituted with K, C1 _10 alkyl with a morpholine [ -N 
(CH2CH2)0] ring attached through nitrogen to the alkyl, 
C1 _10 alkyl with a piperidine ring attached through nitrogen 
to the alkyl, C1 _10 alkyl with a pyrrolidine ring attached 
through nitrogen to the alkyl, C1 _20 alkyl with an OH group 
55 attached to the alkyl, -CH2CH20CH2CH20H, C1 _10 with 
an attached 4-pyridyl group, C1 _10 with an attached 
3-pyridyl group, cl-10 with an attached 2-pyridyl group, 
C1 _10 with an attached cyclohexyl group, -NH-
CH2CH2---( 4-hydroxyphenyl), and -NH-CH2CH2-(3-
60 indolyl). 
In Vitro Uses 
To use the above inhibitors in vitro, they are dissolved in 
an organic solvent such as dimethylsulfoxide or ethanol, and 
are added to an aqueous solution containing serine and/or 
65 cysteine proteases. The fmal concentration of the organic 
solvent should be less than 25%. The inhibitors may also be 
added as solids or in suspension. The serine and cysteine 
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protease inhibitors of this invention would be useful in a 
variety of experimental procedures where proteolysis is a 
significant problem. Inclusion of these inhibitors in a radio-
immunoassay experiments would result in higher sensitivity. 
The use of these inhibitors in plasma fractionation proce-
dures would result in higher yields of valuable plasma 
proteins and would make purification of the proteins easier. 
The inhibitors disclosed here could be used in cloning 
experiments utilizing bacterial cultures, yeast and human 
cells to yield a purified cloned product in higher yield. 
The novel compounds of this invention are effective in the 
prevention of unnecessary proteolysis caused by 
chymotrypsin-like and elastase-like enzymes in the process 
of purification, transport and storage of peptides and pro-
teins as shown in Table II by effective inhibition of chy-
motrypsin and elastase and other cysteine proteases. 
In Vivo Uses 
Effective inhibitors of the proteolytic function of human 
leukocyte elastase and chymotrypsin-like enzymes (Table 
20 
extent of elastase-induced emphysema [Kleinerman et al., 
Am. Rev. Resir. Dis. 121, 381-387 (1980); Lucey et al., Eur. 
Respir. J. 2,421-427 (1989); incorporated herein by 
reference]. Thus the novel inhibitors described here should 
5 be usefull for the treatment of emphysema and inflamma-
tion. Elastase inhibitors have been used orally, by injection, 
or by instillation in the lungs in animal studies (Powers, Am. 
Rev. Respir. Dis., 127, s54-s58 (1983); Powers and Bengali, 
Am. Rev. Respir. Dis. 134, 1097-1100 (1986); these two 
10 articles are incorporated herein by reference). The inhibitors 
described above can be used by any of these routes. 
Drug Delivery 
For therapeutic use, the peptide a-ketoamides may be 
administered orally, topically or parenterally. The term 
15 parenteral as used includes subcutaneous injection, 
intravenous, intramuscular, intrasternal injection or infusion 
techniques. The dosage depends primarily on the specific 
formulation and on the object of the therapy or prophylaxis. 
The amount of the individual doses as well as the adminis-
tration is best determined by individually assessing the 
particular case. 
The pharmaceutical compositions containing the active 
ingredient may be in a form suitable for oral use, for 
example as tablets, troches, lozenges, aqueous or oily 
II) would have anti-inflammatory activity and can be used to 20 
treat and control emphysema, adult respiratory distress syn-
drome and rheumatoid arthritis. Effective inhibitors of the 
proteolytic function of chymotrypsin and pancreatic elastase 
(Table II) are effective for theraputic use in the treatment of 
pancreatitis. 25 suspensions, dispersible powders or granules, emulsions, 
hard or soft capsules or syrups or elixirs. Dosage levels of 
the order to 0.2 mg to 140 mg per kilogram of body weight 
per day are useful in the treatment of above-indicated 
conditions (10 mg to 7 gms per patient per day). The amount 
Peptide a-ketoamide can be used to control protein 
turnover, muscular dystrophy, myocardial tissue damage, 
tumor metastasis, and bone resorption as shown in Table I by 
effective inhibition of lysosomal cathepsin B in buffer. 
Peptide a-ketoamides can also be used as neuroprotectants 
or for the treatment of ischemia, stroke or Alzheimer's 
disease as shown in Table I by effective inhibiton of calpain 
I and calpain II. 
Considerable evidence has shown that leukocyte elastase 
and/or related enzymes play a role in tumor cell metastasis 
[Salo et al., Int. J. Cancer 30, pp 669-673 (1973); Kao et al., 
Biochem. Biophys. Res. Comm. 105, pp 383-389 (1982); 
Powers, J. C. in Modification of Proteins, R. E. Feeney and 
J. R. Whitaker, eds., Adv. Chem. Ser 198,Amer. Chem. Soc., 
Wash., D. C. pp 347-367 (1982); all incorporated herein by 
reference], therefore it is suggested that compounds of this 
invention may have anti-tumor activity. 
Pulmonary emphysema is a disease characterized by 
progressive loss of lung elasticity due to the destruction of 
lung elastin and alveoli. The destructive changes of lung 
parentchyma associated with pulmonary emphysema are 
caused by uncontrolled proteolysis in lung tissues [Janoff, 
Chest 83, 54-58 (1983); incorporated herein by reference]. 
30 of active ingredient that may be combined with carrier 
materials to produce a single dosage form will vary depend-
ing upon the host treated and the particular mode of admin-
istration. 
For injection, the therapeutic amount of the peptide 
35 a-ketoamides or their pharmaceutically acceptable salts will 
normally be in the dosage range from 0.2 to 140 mg/kg of 
body weight. Administration is made by intravenous, intra-
muscular or subscutaneous injection. Accordingly, pharma-
ceutical compositions for parenteral administration will con-
40 tain in a single dosage form about 10 mg to 7 gms of the 
compounds per dose. In addition to the active ingredient, 
these pharmaceutical compositions will usually contain a 
buffer, e.g. a phosphate buffer which keeps the pH in the 
range from 3.5 to 7 and also sodium chloride, mannitol or 
45 sorbitol for adjusting the isotonic pressure. 
A composition for topical application can be formulated 
as an aqueous solution, lotion, jelly or an oily solution or 
suspention. A composition in the form of an aqueous solu-
tion is obtained by dissolving the compounds of this inven-
50 tion in aqueous buffer solution of pH 4 to 6.5 and if desired, 
adding a polymeric binder. An oily formulation for topical 
application is obtained by suspending the compounds of this 
invention in an oil, optionally with the addition of a swelling 
agent such as aluminium stearate and/or a surfactant. 
A number of proteases have been shown to induce emphy-
sema in animals [Marco et al., Am. Rev. Respir. Dis. 104, 
595-598 (1971); Kaplan, J. Lab. Clin. Med. 82, 349-356 
(1973); incorporated herein by reference], particularly 
human leukocyte elastase [Janoff, ibid 115, 461-478 (1977); 
incorporated herein by reference]. Leukocyte elastase and 
other mediators of inflammation also appear to play a role in 55 
diseases such as mucocutaneous lymph node syndrome 
[Reiger et al., Eur. J. Pediatr. 140, 92-97 (1983); incorpo-
rated herein by reference] and adult respiratory distress 
syndrome [Stockley, Clinical Science 64, 119-126 (1983); 
Lee et al., N. Eng. J. Med. 304, 192-196 (1981); Rinaldo, 60 
ibid 301, 900-909 (1982); incorporated herein by reference]. 
SYNTHETIC METHODS 
The a-ketoamide inhibitors are prepared from the corre-
sponding a-ketoamide. The ketoester inhibitors are prepared 
by a two step Dakin-West from the corresponding peptide 
acid (Charles et al., J. Chem. Soc. Perkin 1, 1139-1146, 
1980). This procedure can be utilized with either amino acid 
derivatives, dipeptide derivatives, tripeptide derivatives, or 
tetrapeptide derivatives as shown in the following scheme. 
It is known that in vitro activity of elastase inhibitors 
correlates with in vivo activity in animal models of emphy-
sema and inflammation [Otterness et al., editors, Advances 
in Inflammation Research, Vol. 11, Raven Press 1986; 65 
incorporated herein by reference]. Prophylactic administra-
tion of an inhibitor of elastase significantly diminishes the 
M1-AA---OH~Enol Ester~M,-AA---C0---0-R 
M1-AA-AA---OH~Enol Ester~M,-AA-AA---C0-0-R 
M1-AA-AA-AA-OH~Enol Ester~M,-AA-AA-AA-
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AA---C0---0-R 
M1-AA-AA-AA-AA---OH~Enol Ester~M,-AA-AA­
AA-AA-C0---0-R 
The precursor peptide can be prepared using standard pep- 5 
tide chemistry which is well described in publications such 
22 
with carboxyl blocked peptides to give M1-AA-AA-
OR', M1-AA-AA-AA-OR', or M1-AA-AA-
AA-AA-OR', followed by the removal of the blocking 
group R'. 
The R group in the ketoester structures is introduced 
during the Dakin-West reaction by reaction with an oxalyl 
chloride Cl-CO-C0-0-R. For example, reaction of 
M1-AA-AA-OH with ethyl oxalyl chloride Cl-CO-
C0-0-Et gives the keto ester M1-AA-AA-C0-
as The Peptides, Analysis, Synthesis, Biology, Vol. 1-9, 
published in 1979-1987 by Academic Press and Houben-
Weyl Methoden der Organischen Chemie, Vol. 15, Parts 1 
and 2, Synthese van Peptiden, published by Georg Thieme 
Verlag, Stuttgart in 1974 (both references incorporated 
herein by reference). 
The M1 group can be introduced using a number of 
different reaction schemes. First it could be introduced 
directly on an amino acid as shown in the following scheme 
(top), or the M1 group could be introduced by reaction with 
an amino acid ester, followed by removal of the ester group 
10 0-Et. Reaction of M1-AA-AA-AA-AA-OH with 
Cl-CO-C0-0-Bzl would give the ketoester 
M1-AA-AA-AA-AA-C0-0-Bzl. Clearly a wide 
variety of R groups can be introduced into the ketoester 
structure by reaction with various alkyl or arylalkyl oxalyl 
to give the same product (bottom). 
15 chlorides (Cl-CO-C0-0-R). The oxalyl chlorides are 
easily prepared by reaction of an alkyl or arylalkyl alcohol 
with oxalyl chloride Cl-CO-CO-Cl. For example, 
Bzl-0-CO-CO-Cl and n-Bu-CO-CO-Cl are pre-
pared by reaction of respectively benzyl alcohol and butanol 
H-AA---OH~M,-AA---OH 20 with oxalyl chloride in yields of 50% and 80% [Warren, C. 
H-AA---OR'~M,-AA---OR'~M,-AA---OH B., and Malee, E. J., J. Chromatography 64, 219-222 (1972); incorporated herein by reference]. 
Ketoamides M1-AA-CO-NR3R4, M-AA-AA-
CO-NR3R4, M-AA-AA-AA-CO-NR3R 4, 
The techniques for introduction of the M1 group is well 
documented in the The Peptides, Houben-Weyel, and many 
other textbooks on organic synthesis. For example reaction 
with cyanate orpnitrophenyl cyanate would introduce a 
carbamyl group (M 1 =NH 2 CO-). Reaction with 
Me2 NCOC1 would introduce the Me2NCO- group. Reac-
tion with p-nitrophenyl thiocarbamate would introduce a 
thio carbamyl group (M1 =NH2 CS-). Reaction with 
NH2S02 Cl would introduce the NH2S02- group. Reaction 
with Me2NS02 Cl would introduce the Me2NS02 - group. 
Reaction with a substituted alkyl or aryl isocyanate would 
introduce the X-NH-CO- group where X is a substi-
tuted alkyl or aryl group. Reaction with a substituted alkyl 
25 M-AA-AA-AA-AA-CO-NR3R4 were prepared 
indirectly from the ketoesters. The ketone carbonyl group 
was first protected as shown in the following scheme and 
then the ketoamide was prepared by reaction with an amine 
H-NR3R4. The illustrated procedure should also work with 
30 other protecting groups. In addition, the corresponding 
ketoacid could be used as a precursor. Blocking the ketone 
carbonyl group of the ketoacid and then coupling with an 
amine H-NR3R4 using standard peptide coupling reagents 
would yield an intermediate which could then be deblocked 
35 to form the ketoamide. 
HYYO 13 
/N N......._ 
M1-AA2 R4 
Ri 0 
Most of the aspartyl a-keto amides (12-15, 24-36) were 
synthesized by an adaption of the strategy of Wasserman et 
aL (Scheme 1 and 2) [Wasserman, H. H. and Ho, W.-B., J. 
Org. Chem. 59, 4364-4366(1994) incorporated herein by 
or aryl isothiocyanate would introduce the X-NH-CS-
group where Xis a substututed alkyl or aryl group. Reaction 
with X-502-Cl would introduce the X-S02- group. 
Reaction with a substituted alkyl or aryl acid chloride would 
introduce an acyl group (M=X-CO-). For example, reac- 40 
tion with Me0-CO-CH2 CH2-CO-Cl would give the 
X-CO- group where Xis a C2 alkyl substituted with a C1 
alkyl-OCO- group. Reaction with a substituted alkyl or 
aryl thioacid chloride would introduce a thioacyl group 
(M=X-CS-). Reaction with an a substituted alkyl or aryl 45 
sulfonyl chloride would introduce an X-S02- group. For 
example reaction with dansyl chloride would give the 
X-S02 - derivative where X was a naphthyl group mono 
substituted with a dimethylamino group. Reaction with a 
substituted alkyl or aryl chloroformate would introduce a 50 
X-0-CO- group. Reaction with a substituted alkyl or 
aryl chlorothioformate would introduce a X-0-CS-. 
There are many alternate reaction schemes which could be 
used to introduce all of the above M1 groups to give either 
M1-AA-OH or M1-AA-OR'. 
The M1-AA-OH derivatives could then be used 
directly in the Dakin-West reaction or could be converted 
into the dipeptides, tripeptides, and tetrapeptides 
M 1-AA-AA-OH, M 1-AA-AA-AA-OH, or 
M1-AA-AA-AA-AA-OH which could be be used in 60 
the Dakin-West reaction. The substituted peptides 
M 1-AA-AA-OH, M 1-AA-AA-AA-OH, or 
M1-AA-AA-AA-AA-OH could also be prepared 
directly from H-AA-AA-OH, H-AA-AA-AA-
OH, or H-AA-AA-AA-AA-OH using the reactions 65 
described above for introduction of the M1 group. 
Alternately, the M1 group could be introduced by reaction 
55 reference]. The mixed anhydride of a protected Laspartic 
acid derivative (2-4) was added to the cyanophosphorane 
generated in situ from the corresponding phosphonium 
bromide (1) [Hamper, B. C., J. Org. Chem. 53, 5558-5562 
(1988) incorporated herein by reference]. The aspartylphos-
phorane ( 5-7) was then ozonolyzed at - 78° C. and the 
highly reactive dicarbonylnitrile intermediate was treated 
with the appropriate amine to generate the a-keto amide 
(8-11 ). Removal of the benzyl ester by hydrogenation in the 
presence of Pearlmann's catalyst or by stirring the a-keto 
amide in trifiuoroacetic acid gave the aspartyl a-keto amide 
inhibitors 12-14 and 15 respectively. Alternatively, the Boe 
group was removed using HCI gas in ethyl acetate (Scheme 
US 6,235,929 Bl 
23 
2) and the deprotected amines (22, 23) were either hydro-
genated to give the unprotected aspartyl a-keto amides (24, 
25) or coupled with a variety of acids, followed by hydro-
genation to give the required inhibitors (26-36). 
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26 R3 = CH2CH2Ph, R4 = PhCH2S02 
27 R3 = CH2CH2Ph, R4 = (CH3)2CH2CO-Gly 
28 R3 = CH2CH2Ph, R4 = PhCH2CH2CO-Ala-Ala 
29 R3 = CH2CH2Ph, R4 = PhCH2CH2CO-Val-Gly 
31 R3 = CH2CH2Ph, R4 = PhCH2CH2CO-Val-Ala 
33 R3 = CH2CH2Ph, R4 = p-Cl-PhCH2CH2CO-Val-Ala 
35 R3 = CH2CH2Ph, R4 = Ac-Tyr-Val-Ala 
36 R3 = CH2CH2CH2Ph, R4 = Ac-Tyr-Val-Ala 
Four of the peptidyl a-keto amides (54-57) were prepared 20 
by an alternative method (Scheme 3) [Gmeiner, P., Junge, D. 
& Kartner, A J. Org. Chem. 59, 6766-6776 (1994) by 
reference]. Aspartic acid was benzylated to give (37) fol-
lowed by reduction to the dial derivative 38. The C-4 alcohol 
was selectively protected as the dimethyl t-butylsilyl ether 25 
(39) and the C-1 alcohol was oxidized to the aldehyde (40). 
After stirring in neat trimethylsilylcyanide, the cyanohydrin 
( 41) was hydrolyzed and the crude intermediate was coupled 
to the appropriate amine to give a dihydroxy amide ( 42, 43). 30 
After debenzylation in the presence of Pearlmann's catalyst, 
the dihydroxyamine ( 44, 
38 
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49 Ri = CH2CH2CH2Ph, R1 = Cbz-Val-Ala 
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54 Ri = CH2CH2Ph, R1 = Cbz-Ala 
55 Ri = CH2CH2CH2Ph, R1 = Cbz-Ala 
56 Ri = CH2CH2Ph, R1 = Cbz-Val-Ala 
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45) was coupled with the required acid to give the corre-
sponding peptidyl dihydroxy amide ( 46-49). Several 
attempts at directly oxidizing the dihydroxy amide to the 
final a-keto amide product were not successful. Mild to 
strong basic oxidation conditions produced mostly the start-
ing dial, byproducts such as the dehydrated aldehyde or 
cyclized lactone, mixed with the desired a-keto amide. 
Under mild acidic oxidation conditions (chromic acid), the 
starting dial and the lactone were obtained. Under strong 
acidic oxidation conditions (Jones reagent) only decom-
posed products were obtained. Thus, it was necessary to 
oxidize the primary and secondary alcohols separately. 
Therefore, the primary alcohol was protected again (50-53) 
and the final form of the a-keto amide was obtained by a 
consecutive double oxidation where the silyl protecting 
group was simultaneously removed at the second oxidation 
stage with chromic acid in acetic acid. 
The peptide acids (R4-0H in Scheme 2 and R2-0H in 
Scheme 3) were prepared for the most part by standard 
peptide coupling methods. 
28 
(50:1 v/v) afforded 14.63 g (y=53%) of Z-Leu-Phe-
enolester. The product was a yellow oil. Single spot on TLC, 
R_r0.77 (CHCL3/CH3 0H 50:1). NMR (CDC13) ok. 
To a stirred pale yellow solution of the Z-Leu-Phe-
5 enolester (14.63 g, 25.73 mmole) in anhydrous ethanol (50 
ml) was added a solution of sodium ethoxide (0.177 g, 2.6 
mmole) in ethanol (5 ml). The orange solution was stirred 
for 3 hours at room temperature, then the ethanol was 
evaporated and the residue was treated with ethyl ether (300 
10 ml). The ether layer was washed with water (2x100 ml), 
saturated sodium chloride (2'100 ml), dried over magnesium 
sulfate, and concentrated, leaving a orange oil. Chromatog-
raphy on a silica gel column with CHC13/CH3 0H (50:1 v/v) 
afforded 7.76 g (y=64%) of the a-ketoester Z-Leu-Phe-
15 COOEt. The product was a yellow oil. Single spot on TLC, 
R_r0.44 (CHC13/CH3 0H 50:1). NMR (CDC13 ) ok. MS 
(FAE, calcd. for C26H32N2 0 6 :468.6), m/e=469 (M+l). 
The a-carbonyl group of Z-Leu-Phe-COOEt was 
protected by the following procedure. To a solution of 
20 Z-Leu-Phe-COOEt (1 g, 2.13 mmole) in 5 ml of 
CH2 Cl2 was added 1,2-ethanedithiol (0.214 ml, 2.55 
mmole), followed by 0.5 ml of boron trifluoride etherate. 
The solution was stirred overnight at room temperature. 
Water (20 ml) and ethyl ether (20 ml) were added. The 
25 organic layer was separated, washed with water (2x10 ml), 
saturated sodium chloride (2x10 ml), dried over magnesium 
sulfate, and evaporated to afford 0.98 g (y=84%) yellow 
semisolid. 
The protected a-ketoester (0.98 g, 1.8 rnmole) was dis-
30 solved in ethanol (5 ml), cooled tc 0-5° C. in an ice bath, and 
ethylamine was bubbled through the solution until 2.43 g (54 
mmole) had been added. The reaction mixture was allowed 
to warm to room temperature slowly, and stirred overnight. 
The mixture was filtered, a white precipitate was removed, 
35 leaving a yellow semisolid. Chromatography on a silica gel 
column with CHC13 /CH3 0H (30:1 v/v) afford 0.63 g 
(y=75%) of Z-Leu-Phe-CONH-Et. The product was a 
pale yellow solid. Single spot on TLC, R_r0.60 (CHC13 / 
CH3 0H 20:1); mp 145-147° C. Anal. calcd. for 
40 C26H33N3 0 5 :467.56; C, 66.79; H, 7.11; N,8.99; found: C, 
66.59; H, 7.09; N, 8.95. NMR (CDC13) ok. MS (FAE) 
m/e=468 (M+l). 
EXAMPLE 2 
45 Z-Leu-Phe-CONH-nPr 
The following detailed examples are given to illustrate the 50 
invention and are not intended to limit it in any manner. 
This compound was synthesized from the protected 
a-ketoester and propylamine in 92% yield by the procedure 
described in Example 1. Single spot on TLC, R_r0.50 
(CHC13/CH3 0H 50:1); mp 152-153° C. Anal. calcd. for 
C27H35N3 0 5 :481.57; C, 67.33; H, 7.33; N, 8.72. Found: C, 
67.21; H, 7.38; N, 8.64. NMR (CDC13) ok. MS (FAE) 
m/e=482 (M+l). EXAMPLE 1 
Z-Leu-Phe-CONH-Et EXAMPLE 3 
To a stirred solution of Z-Leu-Phe-OH (20 g, 48.5 
mmole), 4-dimethylaminopyridine (0.587 g, 4.8 mmole),and 
pyridine (15.7 ml, 194 mmole) in anhydrous THF (100 ml) 
was added ethyl oxalyl chloride (11.4 ml, 101.8 mmole) at 
55 Z-Leu-Phe-CONH-nBu 
This compound was synthesized from the protected 
a-ketoester and butylamine in 67% yield by the procedure 
described in Example 1. Single spot on TLC, R_r0.50. 
(CHC13/CH3 0H 50:1); mp 152-153° C. Anal. calcd. for 
C28H37N3 0 5 :495.59; C, 67.85; H, 7.52; N, 8.48. Found: C, 
67.70; H, 7.57; N, 8.43. NMR (CDC13) ok. MS (FAE) 
m/e=496 (M+l). 
EXAMPLE 4 
a rate sufficient to initiate refluxing. The mixture was gently 
refluxed for 4 hours, cooled to room temperature, and water 60 
(80 ml) was added. The reaction mixture was stirred vigor-
ously for 30 min, and extracted with ethyl acetate (3x100 
ml). The combined organic layers were washed with water 
(2x100 ml), saturated sodium chloride (2x100 ml), decol-
orized with decolorizing carbon, dried over magnesium 
sulfate, and concentrated, leaving a dark orange oil. Chro-
matography on a silica gel column with CHC13/CH3 0H 
65 Z-Leu-Phe-CONH-iBu 
This compound was synthesized from the protected 
a-ketoester and isobutylamine in 53% yield by the proce-
US 6,235,929 Bl 
29 30 
EXAMPLE 10 
Z-Leu-Abu-CONH-iBu 
This compound was synthesized from the conesponding 
dure described in Example 1. Single spot on 1LC, R_r0.54 
(CHC13 /CH3 0H 50:1); mp 152° C. Anal. calcd. for 
C28H37N3 0 5 :495.59; C, 67.85; H, 7.52; N, 8.48. Found: C, 
67.77; H, 7.56; N, 8.40. NMR (CDC13 ) ok. MS (FAE) 
m/e=496 (M+l). 
EXAMPLE 5 
Z-Leu-Phe-CONH-Bzl 
5 
protected a-ketoester and isobutylamine in 65% yield by the 
procedure described in Example 1. Single spot on TLC, 
R_r0.25 (CHC13/CH3 0H 50:1); mp 133-135° C. Anal. 
calcd. for C23H35N3 0 5 :433.52; C, 63.72; H, 8.14; N, 9.69. 
Found: C, 63.46; H, 8.10; N, 9.60. NMR (CDC13) ok. MS 
10 
(FAE) m/e=434 (M+l). This compound was synthesized from the protected 
a-ketoester and benzylamine in 40% yield by the procedure 
described in Example 1. After reacting overnight, ethyl 
acetate (60 ml) was added. The mixture was filtered to 
remove a white precipitate. The solution was washed with 
cooled 1 N HCl (3x25 ml), water (lx20 ml), saturated 15 
sodium chloride (2x20 ml), and dried over magnesium 
sulfate. The solution was evaporated leaving a yellow solid. 
Chromatography on a silica gel column with CHC13/CH3 0H 
30:1 v/v) afforded a yellow solid. Single spot on TLC, 
R_r0.45 (CHC13/CH3 0H 30:1); mp 160-162° C. Anal. 20 
calcd. for C31H35N3 0 5 :529.61; C, 70.30; H, 6.66; N, 7.93. 
Found: C, 70.18; H, 6.67; N, 7.99. NMR (CDC13) ok. MS 
(FAE) m/e=530 (M+l). 
EXAMPLE 6 
Z-Leu-Phe-CONH---(CH2 ) 2 Ph 
This compound was synthesized from the protected 
a-ketoester and phenethylamine in 50% yield by the pro-
cedure described in Example 5. Single spot on TLC, R_r0.50 
(CHC13/CH3 0H 30:1); mp 151-153° C. Anal. calcd. for 
C32H37N3 0 5 :543.66; C, 70.70; H, 6.86; N, 7.73. Found: C, 
70.54; H, 6.88; N, 7.74. NMR (CDC13 ) ok. MS (FAE) 
m/e=544 (M+l). 
EXAMPLE 7 
Z-Leu-Abu-CONH-Et 
This compound was synthesized from protected 
a-ketoester derived from Z-Leu-Abu-C02 Et and ethy-
lamine in 64% yield by the procedure described in Example 
1. Single spot on TIC, R_r0.36 (CHC13/CH3 0H 50;1); mp 
130--132° C.Anal. calcd. for C21H31N3 0 5 :405.45; C, 62.20; 
H, 7.71; N, 10.36. Found: C, 61.92; H, 7.62; N, 10.31. NMR 
(CDC13) ok. MS (FAE) m/e=406 (M+l). 
EXAMPLE 8 
Z-Leu-Abu-CONH-nPr 
EXAMPLE 11 
Z-Leu-Abu-CONH-Bzl 
This compound was synthesized from the corresponding 
protected a-ketoester and benzylamine in 29% yield by the 
procedure described in Example 5. Single spot on TLC, 
R_r0.56 (CHC13/CH3 0H 30:1); mp 140--141° C. Anal. 
calcd. for C26H33N3 0 5 :467.54; C, 66.79; H, 7.11; N, 8.99. 
Found: C, 66.65; H, 7.07; N, 8.93. NMR (CDC13) ok. MS 
(FAE) m/e=468 (M+l). 
EXAMPLE 12 
Z-Leu-Abu-CONH---( CH2) 2Ph 
This compound was synthesized from the corresponding 
25 protected a-ketoester and phenethylamine in 51 % yield by 
the procedure described in Example 5. Single spot on TLC, 
R_r0.44 (CHC131CH3 0H30:1); mp 156-157° C.Anal. calcd. 
for C27H35N3 0 5 :481.59; C, 67.34; H, 7.33; N, 8.72. Found: 
C, 67.38; H, 7.33; N, 8.78. NMR (CDC13 ) ok. MS (FAE) 
30 m/e =482 (M+l). 
EXAMPLE 13 
Z-Leu-Abu-CONH---(CH2h-N(CH2 CH2 ) 2 0 
This compound was synthesized from protected 
35 
a-ketoester and 4(3-aminopropyl)morpholine in 33% yield 
by the procedure described in Example 1. After reacting 
overnight, ethyl acetate (80 ml) was added. The mixture was 
filtered to remove a white precipitate. The solution was 
washed with water (3x20 ml), saturated sodium chloride 
40 (2x20 ml), and dried over magnesium sulfate. The solution 
was evaporated leaving a yellow oil. Chromatography on a 
silica gel column with CHC13/CH3 0H (10:1 v/v) afforded a 
yellow semisolid, which was recrystallized from ethyl 
acetatelhexane to obtain a pale yellow solid. Single spot on 
45 TLC, R_r0.42(CHC13/CH3 0H10:1); mp 125-126° C.Anal. 
calcd. for C26H4 N4 0 6 :504.63; C, 61.88; H, 7.99; N, 11.10. 
Found: C, 61,69; H, 7.95; N, 11.07. NMR (CDC13 ) ok. MS 
(FAE) m/e=505 (M+l). 
This compound was synthesized from the corresponding 50 
protected a-ketoester and propylamine in 47% yield by the 
procedure described in Example 1. Single spot on TLC, 
R_r0.28 (CHC13/CH3 0H 50:1); mp 134-135° C. Anal. 
calcd. for C22H33N3 0 5 :419.50; C, 62.98; H, 7.93; N, 10.02. 
Found: C, 62.84; H, 7.97; N, 9.94. NMR (CDC13) ok. MS 55 
(FAE) m/e=420 (M+l). 
EXAMPLE 14 
Z-Leu-Abu-CONH---( CH2hCH3 
This compound was synthesized from the corresponding 
protected a-ketoester and octylamine in 67% yield by the 
procedure described in Example 5. It was white solid. Single 
spot on TLC, R_r0.55 (CHC13/CH3 0H 30:1); mp 134--135° 
C. Anal. calcd. for C27H43N3 0 5 : 489.66; C, 66.23; H, 8.85; 
N, 8.58. Found: C, 66.19; H, 8.81; N, 8.61. NMR (CDC13 ) 
ok. MS (FAE) m/e=490 (M+l). EXAMPLE 9 
Z-Leu-Abu-CONH-nBu 60 
This compound was synthesized from the corresponding 
protected a-ketoester and butylamine in 42% yield by the 
procedure described in Example 1. Single spot on TLC, 
R_r0.54 (CHC13/CH3 0H 50:1); mp 135-136° C. Anal. 
calcd. for C23H35N3 0 5 :433.53; C, 63.71; H, 8.13; N, 9.69. 65 
Found: C, 63.48; H, 8.07; N, 9.67. NMR (CDC13) ok. MS 
(FAE) m/e=434 (M+l). 
EXAMPLE 15 
Z-Leu-Abu-CONH---(CH2) 20H 
This compound was synthesized from the corresponding 
protected a-ketoester and ethanolamine in 29% yield by the 
procedure described in Example 13. The product was a 
white sticky solid. Single spot on TLC, R_r0.42 (CHC13 / 
CH3 0H 10:1); mp 151-153° C. Anal: calcd. for 
US 6,235,929 Bl 
31 
C21H31N3 0 6 :421.49; C, S9.84; H, 7.41; N, 9.97. Found: C, 
S9.11; H, 7.44; N, 9.81. NMR (CDC13) ok. MS (FAE) 
m/e=422 (M+l). 
EXAMPLE 16 
Z-Leu-Abu-CONH---( CH2) 2 0( CH2) 2 0H 
This compound was synthesized from the corresponding 
protected a-ketoester and 2-(2-aminoethoxy)ethanol in 34% 
yield by the procedure described in Example 13. The prod-
uct was white sticky solid. Single spot on TLC, R_r0.42 
(CHC13/CH3 0H 10:1); mp 103-10S 0 C. Anal.: calcd. for 
C23H35N3 0 7 : 46S.5S; C, S9.34; H, 7.58; N, 9.03. Found: C, 
S9.23; H, 7.58; N, 9.01. NMR (CDC13 ) ok. MS (FAE) 
m/e=466 (M+l). 
EXAMPLE 17 
Z-Leu-Abu-CONH---( CH2) 17CH3 
This compound was synthesized from the corresponding 
protected a-ketoester and octadecylamine in 12% yield by 
the procedure described in Example S. The product was a 
pale yellow solid. Single spot on TLC, R_r0.54 (CHC13 / 
CH3 0H 30:1); mp 134-136° C. Anal: calcd. for 
C37H63N3 0 5 :629.92; C, 70.SS; H, 10.08; N, 6.67. Found: C, 
70.71; H, 10.14; N, 6.7S. NMR (CDC13 ) ok. MS (FAE) 
m/e=630.2 (M+l). 
EXAMPLE 18 
Z-Leu-Abu-CONH-CH2-C6HiOCH3) 2 
This compound was synthesized from the corresponding 
protected a-ketoester and 3,S-dimethoxybenzylamine in 
4S% yield by the procedure described in Example S. The 
product was yellow sticky solid. Single spot on TLC, 
R_r0.44 (CHC13/CH3 0H 30: 1); mp 1S3-1SS 0 C. Anal.: 
calcd. for C28H37N3 0 7 :S27.62; C, 63.74; H, 7.07; N, 7.96. 
Found: C, 63.66; H, 7.09; N, 7.92. NMR (CDC13) ok. MS 
(FAE) m/e=S28.8 (M+l). 
EXAMPLE 19 
Z-Leu-Abu-CONH-CH2-C4 H4 N 
This compound was synthesized from the corresponding 
protected a-ketoester and 4-(aminomethyl)pyridine in 4S% 
yield by the procedure described in Example 13. The prod-
uct was greenish yellow solid. Single spot on TLC, R_rO.SS 
(CHC13/CH3 0H 10:1); mp 124-126° C. Anal: calcd. for 
C25H32N4 0 5 :468.5S; C, 64.08; H, 6.88; N, 11.96. Found: C, 
63.88; H, 6.87; N, 11.96. NMR (CDC13) ok. MS (FAE) 
m/e=469 (M+l). 
Methods and Starting Materials 
Unless otherwise noted, materials were obtained from 
commercial suppliers and used without further purification. 
The purity of each compound was checked by TLC, mp, 1H 
NMR and mass spectroscopy. TLC were performed on 
Baker Si2SOF silica gel plates. Melting points were obtained 
on a Buchi capillary apparatus and are not corrected. 1H 
NMR spectra were determined on a Varian Gemini 300. 
Chemical shifts are expressed in ppm relative to internal 
tetramethylsilane. Mass spectra were obtained on a Varian 
MAT 112S spectrometer. Column chromatography was per-
formed on silica gel (32-63 microns). 
The physical properties and proton NMR data for the 
peptide a-keto amide inhibitors are given in Tables III and 
IV repectively. 
Triphenyl Cyanomethyl Phosphonium Bromide (1) 
[Novikov, S.S. and Shvekhgeimer, G. A Izvest. Akad. Nauk 
32 
S.S.R.R., OtdeL Khim. Nauk, 2061-2063 (1960) incorpo-
rated herein by reference]. A solution of bromoacetonitrile 
(6.07 g, SO mmol) and triphenyl phosphine (16.07 g, 60 
mmol) in SO ml of benzene was refluxed under an argon 
5 atmosphere for 30 minutes. After cooling to room 
temperature, the product was collected by filtration and 
dried under reduced pressure to give 16.51 g ( 43 mmol, 86% 
yield) of a white powder: 1H NMR (DMSO-d6) oS.81 (d, 
2H, P-CH2-CN), 7.86 (m, 12H, aromatic), 8.00 (m, 3H, 
10 aromatic);FAEMS (calculated for C20H17NP, 302.1099) 
m/e 302.1097 (M+-HBr+l). 
S-Cy ano-S-trip he ny lphosphoran y lide ne-4-keto-3-(N -t-
butyloxy lcarbony lamino )pentanoic Acid Benzyl Ester (S). 
To a suspension of triphenyl cyanomethyl phosphonium 
15 bromide (1, 0.68 g, 1.8 mmol) in anhydrous THF (10 mL) 
cooled in an ice bath was added triethylamine (396 mg, S46 
µL, 3.9 mmol) and the mixture stirred in an ice bath for lS 
min. To a solution of N-t-butyloxycarbonyl-~­
benzylaspartic acid (2, S7S mg, 1.8 mmol) in THF (lS mL) 
20 cooled to -1S 0 C. was added N-methyl morpholine (180 mg, 
196 µL, 1.8 mmol) followed by iso-butylchloroformate (243 
mg, 231 µL, 1.8 mmol). The resulting solution was stirred at 
-1S 0 C. for S min before being added dropwise with stirring 
to the previously prepared cyanomethylphosphorane solu-
25 tion. The mixture was stirred at 0° C. for lS min and then 
allowed to warm to room temperature and then stirred for a 
further 16 h. The precipitate was removed by filtration and 
the solvent removed under reduced pressure. The mixture 
was purified by chromatography on silica gel (O-SO% ethyl 
30 acetate in hexane) to yield the product as a clear oil which 
solidified on drying (0.76 g, 70%): mp 42-44° C.; 1 H NMR 
(CDC13) ol.39 (s, 9H, Boe CH3 's), 2.99 (d, 2H, ~-CH2), 
S.06 (m, 3H, a-CH & benzyl CH2), S.62 (d, lH, NH), 7.28 
(m, SH, benzyl aromatic CH's), 7.52 (m, lSH, PPh3 aro-
35 matic CH's); MS (El, calculated for C36H35N2 0 5 P, 
606.2284) m/e 606.2292 (M+). 
S-Cyano-S-tripheny lphosphorany lidene-4-keto-3-(N -
benzyloxylcarbonylamino )pentanoic Acid t-Butyl Ester ( 6). 
This was synthesized in a manner identical to that used for 
40 S, except that N-benzyloxycarbonyl-~-t-butyl aspartic acid 
(3, 4.01 g, 12.4 mmol) was used instead of N-t-
butyloxycarbonylaspartic acid ~-benzyl ester (2, Boe-Asp 
(Bzl)-OH) to give the product as pale yellow flakes ( 4.70 
g, 7.74 mmol, 62% yield) after purification by silica gel 
45 chromatography (R_r0.43, Et0Ac:hexane=2:1): 1H NMR 
(DMSO-d6) ol.3S (s, 9H, Boe CH3 's), 2.39 (dd, lH, ~-CH2), 
2.69 (dd, lH, ~-CH2), S.04 (m, 3H, a-CH & benzyl CH2), 
7.33 (m, SH, benzyl aromatic CH's), 7.6S (m, lSH, PPh3 
aromatic CH's), 7.80 (m, lH, NH); FAEMS (calculated for 
50 C36H36N2 0 5 P, 607.2362) m/e 607.23SS (M++l). 
S-Cyano-S-tripheny lphosphorany lidene-4-keto-3-(N -
methyloxylcarbonylamino )pentanoic Acid Benzyl Ester (7). 
This was synthesized in a manner identical to that used for 
S, except that methyloxycarbonylaspartic acid ~-benzyl 
55 ester ( 4, S06 mg, 1.8 mmol) instead of 2 to give the product 
as a clear oil which was recrystallized from ether/hexane 
(447 mg, 44%): 1H NMR (CDC13 ) 03.00 (m, 2H, ~-CH2), 
3.57 (s, 3H, CH3 0), S.OS (s, 2H, benzyl CH2), S.11 (m, lH, 
a-CH), S.8S (d, lH, NH), 7.23 (m, SH, benzyl aromatic 
60 CH's), 7.48 (m, lSH, PPh3 aromatic CH's); FAEMS 
(calculated for C33H30N2 0 5 P, S6S.1892) m/e S6S.1891 
(M++l). 
EXAMPLE 20 
65 Boc-Asp(Bzl)-CONH-CH2 CH2 Ph (8) 
Ozone gas was bubbled through a solution of S (606 mg, 
1 mmol) in CH2 Cl2 (20 mL) cooled to - 78° C. until its blue 
US 6,235,929 Bl 
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color persists within the solution. The excess ozone was 
purged using argon and phenethylamine (181 mg, 189 µL, 
1.S mmol) was added. The resulting solution was stirred at 
34 
EXAMPLE 2S 
3-( 4- Chlo rop hen yl)p rop ano ic 
( 4-Chlorohydrocinnamic Acid) 
Acid 
- 78° C. for 1 hand then allowed to warm to r.t. The solvent 
was removed under reduced pressure and the residue chro- 5 
matographed on silica gel (0-30% ethyl acetate in hexane) 
To a solution of 1.80 g (10 mmol) of 4-chlorocinnamic 
acid in SO mL of THF was added Pd/C (1.04 g, S% w/w) and 
the solution was stirred under a hydrogen atmosphere until 
no further H2 take-up was observed (-1 h). The solution was 
filtered through Celite and the solvent removed under 
reduced pressure to yield 1.82 g (9.8 mmol, 98%) of a white 
solid: mp. 103-10S0 C.; 1 H NMR (DMSO-d6) 02.51 (t, 2H, 
~-CH2), 2.79 (t, 2H, a-CH2), 7.28 (dd, 4H, aromatic CH's), 
12.12 (s, lH, COOH); MS (EI, calculated for C9H9 Cl02, 
184.0291) m/e 184.0288 (M+). 
to yield the product as a clear oil which was then recrystal-
lized from ether/hexane (14S mg, 32%): mp 132-134° C.; 
1 H NMR (CDC13 ) ol.43 (s, 9H, Boe CH3's), 2.81 (t, 2H, 
NHCH2-CH2-Ph), 3.12 (dd, lH, 1 of CH2-C02Bzl), 10 
3.44 (dd, lH, 1 of CH2-C02Bzl), 3.SS (t, 2H, NH-CH2-
CH2Ph), S.10 (s, 2H, benzyl CH2), S.13 (m, lH, a-CH), 
S.51 (d, lH, urethane NH), 6.92 (br, lH, amide NH), 7.20 
(m, SH, phenethyl aromatic CH's), 7.30 (m, SH, benzyl 
aromatic CH's); FABMS (calculated for C25H31N20 6, 15 
4SS.2182) m/e 4SS.2146 (M+ +1). 
EXAMPLE 26 
HC1.H-Asp-CONH-CH2CH2Ph (24) 
The keto amide (8) (227 mg, 0.5 mmol) was dissolved in 
ethyl acetate (10 mL) and cooled in an ice bath. Dry HCl gas 
was bubbled through until the solution was saturated and 
EXAMPLE 21 
Boc-Asp(Bzl)-CONH-CH2CH2CH2Ph (9) 
This was prepared in a manner identical to that for 8, 
except using 3-phenyl-1-propylamine (203 mg, 213 µL, 1.S 
mmol) instead of phenethylamine to yield the product as a 
white crystalline solid (117 mg, 2S%): mp 87-88° C.; 1H 
NMR (CDC13): 1.4S (s, 9H, Boe CH3's), 1.81 (tt, 2H, 
NHCH2-CH2-CH2Ph), 2.63 (t, 2H, NHCH2CH2-
CH2-Ph), 2.70 ( dd, lH, 1 of CH2-C02Bzl), 3.0S ( dd, lH, 
20 then the solution was stirred at r.t. until the starting material 
had been consumed as indicated by tic (-30 min). The 
solvent was removed under reduced pressure to give 
HC1.H-Asp(Bzl)-CONH-CH2CH2Ph (22) as a white 
solid: FABMS (calculated for C20H23N20 4 , 3SS.16S8) m/e 
25 3SS.16Sl (M++l-HCl). Without further purification, this 
crude product was used for the debenzylation reaction in a 
same manner as described for 12 to give 12 mg (0.04 mmol, 
8%) of a white solid after recrystallization from methanol/ 
ether. 
1 of CH2-C02Bzl), 3.27 (t, 2H, NH-CH2-CH2CH2Ph), 
4.48 (m, lH, a-CH), S.11 (s, 2H, benzyl CH2), S.6S (br, lH, 
urethane NH), 6.49 (br, lH, amide NH), 7.28 (m, lOH, 
aromatic CH's); FABMS (calculated for C26H33N20 6, 30 
469 .2339) m/e 469 .23S9 (M+ + 1 ). EXAMPLE 27 
HC1.H-Asp-CONH-CH2CH2CH2Ph (2S) 
EXAMPLE 22 
Cbz-Asp(t-Bu)-CONH-CH2CH2Ph (10) 
This was prepared in a manner identical to 24 except 
using 234 mg (0.5 mmol) of 9 to give lS mg (O.OS mmol, 
35 
10%) of the product. 
EXAMPLE 28 
PhCH2S02-Asp-CONH-CH2CH2Ph (26) 
This was prepared in a manner identical to that used for 
8, except using 6 (2.53 g, 4.17 mmol) instead of S to give the 
product as a white crystalline solid ( 433.8 mg, 0.9S mmol, 
22% yield) after purification by silica gel chromatography 
(R_r0.21, EtOAc: hexane=1:3) and recrystallization from 
ethyl acetate and hexane: mp 89-90° C.; 1H NMR (CDC13 ) 40 
ol.37 (s, 9H, t-Bu CH3 's), 2.83 (t, 2H, NHCH2-CH2-Ph), 
The keto amide (8) (109 mg, 0.24 mmol) was dissolved in 
ethyl acetate (S mL) and cooled in an ice bath. Dry HCl gas 
was bubbled through until the solution was saturated and 
then the solution was stirred at r.t. until the starting material 
had been consumed as indicated by tlc (-30 min). The 
solvent was removed under reduced pressure. The residue 
2.99 (dd, lH, 1 of ~-CH2), 3.39 (dd, lH, 1 of ~-CH2), 3.56 
(q, 2H, NH-CH2-CH2Ph), S.08 (m, lH, a-CH), S.12 (s, 
2H, benzyl CH2), S.7S (d, lH, urethane NH), 6.98 (t, lH, 
amide NH), 7.29 (m, lOH, aromatic CH's); FABMS 
45 (calculated for C25H31 N20 6, 4SS.2182) m/e 4SS.2201 (M+ + 
(22) was dissolved in dry CH2Cl2 (S mL) and triethylamine 
(61 mg, 84 µL) added. The solution was then added drop-
wise to a solution of benzyl sulfonyl chloride (46 mg, 0.24 
mmol) in dry CH2Cl2 (S mL) cooled in an ice bath. The 
resulting solution was allowed to stir at r.t. for 16 h. It was 
washed with lM HCl, S% sodium bicarbonate solution and 
1). 
EXAMPLE 23 
General Procedure for the Debenzylation of Aspartyl 
~-Benzyl Ester Derivatives to Yield 12-14, 24--36 (Boc-
Asp-CONH-CH2CH2Ph, 12) 
To a solution of the benzyl ester Boc-Asp(0Bzl)-
CONH-CH2CH2Ph (8, 7S mg, 0.16 mmol) in methanol (S 
mL) was added Pd(OH)2/C (7.5 mg, 10% w/w) and the 
solution was stirred under a hydrogen atmosphere until no 
further H2 take-up was observed (-1 h). The solution was 
filtered through Celite and the solvent removed under 
reduced pressure to yield the product 12 as a clear oil which 
was recrystallized from methanol/ether (SO mg, 83%). 
EXAMPLE 24 
Cbz-Asp-CONH-CH2CH2Ph (lS) 
The t-butyl ester (10, 100 mg, 0.22 mmol) in trifiuoro-
acetic acid (S mL) was stirred in an ice bath for 30 minutes. 
Trifiuoroacetic acid was removed under reduced pressure, 
the crude product was recrystallized from EtOAc/hexane to 
give 76.8 mg (0.19 mmol, 87% yield) of a pale yellow solid. 
50 saturated brine, then dried (MgS04 ) and the solvent 
removed under reduced pressure to yield the product as a 
white solid (Sl mg, 42%): mp 128-130° C. 1 H NMR 
(CDC13) 02.61 & 2.99 (ABX, 2H, ~-CH2), 2.86 (t, 2H, 
CH2Ph), 3.57 (m, 2H, NH-CH2), 4.74 (m, lH, a-CH), S.14 
55 (2xs, 4H, benzyl CH2's), 6.53 & 6.74 (m, 2H, NH's), 7.29 
(m, lSH, aromatic CH's); FABMS m/e S09 (M+ +1). 
60 
This product was subjected to the debenzylation condi-
tions as described for 12 to give 10 mg (24%) of white solid. 
EXAMPLE 29 
General Procedure for the Synthesis of 27-3S (Ac-Tyr-
Val-Ala-Asp-CONH-CH2CH2Ph, 3S) 
The ketoamide (8) (227 mg, 0.5 mmol) was dissolved in 
ethyl acetate (10 mL) and cooled in an ice bath. Dry HCl gas 
65 was bubbled through until the solution was saturated and 
then the solution was stirred at r.t. until the starting material 
had been consumed as indicated by tlc (-30 min). The 
US 6,235,929 Bl 
35 36 
solvent was removed under reduced pressure to give 22. To 
a solution ofAc-Tyr-Val-Ala-OH (197 mg, 0.5 mmol) 
in dry THF (10 mL) and DMF (2 mL) cooled to -1S 0 C. was 
added N-methyl morpholine (Sl mg, SS µL, 0.5 mmol) 
followed by iso-butyl chlorofornate (68 mg, 6S µL, 0.5 5 
mmol) and the solution stirred at -1S0 C. for S min. A 
previously prepared solution of 22 and N-methyl morpho-
line (Sl mg, SS µL, 0.5 mmol) in dry THF (S mL) was added, 
the solution stirred at -1S 0 C. for lS-30 min and then at r.t. 
removed from the filtrate with a rotary evaporator. The crude 
residue was purified by gel chromatography 
(Et0Ac:hexane=2:1) to give 10.12 g (0.03S mole, 89%) of 
a colorless oil: R_r0.27 (Et0Ac:hexane=1:4); 1H NMR 
(CDC13) ol.4S (m, lH, ~-CH), 1.96 (m, lH, ~-CH), 2.90 
(m,, lH, a-CH), 3.28 (br, 2H, -OH), 3.59 (m, SH, Ph-C 
H2-N, CH2-0H), 7.28 (m, lOH, aromatic H). MS (CI, 
Calculated Tor C18H24N02 , 286.1807) m/e 286.1843 (M+ + 
1). 
for 16 h. The solution was filtered and the solvent removed 10 2-(N,N-Dibenzylamino )-4-[( t-butyldimethylsilyl)oxy] 
under reduced pressure to yield the product which was 
recrystallized from methanol/ether to give 340 mg (93%) of 
Ac-Tyr-Val-Ala-Asp(Bzl)-CONH-CH2 CH2 Ph: 
mp 192-194° C.; 1 H NMR (DMSO) o0.77 (m, 6H, Val 
CH3 's), 1.19 (m, 3H, Ala CH3), 1.74 (s, 3H, Ac CH3), 1.93 
(m, lH, Val ~-CH), 2.62 (obs, 2H, CH2Ph), 2.77 & 3.18 (m, 
4H, Tyr &Asp ~-CH2's), 3.37 (m, 2H, NH-CH2), 3.7S, 4.09, 
4.19 & 4.53 (m, 4H, a-CH's), S.06 (s, 2H, benzyl CH2), 6.62 
& 7.01 (2xd, 4H, Tyr aromatic CH's), 7.20 (m, SH, phen-
ethyl aromatic CH's), 7.3S (s, SH, benzyl aromatic CH's), 
7.83 (m, lH, NH), 8.04 (m, 4H, NH's), 9.lS (s, lH, Tyr OH); 
FABMS m/e 730 (M++l). 
This product was subjected to the debenzylation condi-
tions as described for 12 to give 170 mg (S7%) of a white 
solid. 
EXAMPLE 30 
Ac-Tyr-Val-Ala-Asp-CONH-CH2 CH2 CH2 Ph 
(36) 
This was prepared in a manner identical to 3S except 
using (9) (234 mg, 0.5 mmol) instead of (8) to yield the 
product which was recrystallized from methanol/ether to 
give the product as a white solid. 
EXAMPLE 31 
N,N-Dibenzylaspartic Acid Dibenzyl Ester (37) 
[Gmeiner, P., Junge, D. and Kartner, A. J. Org. Chem. S9, 
6766-6776 (1994) incorporated herein by reference]. To a 
solution of 26.62 g (0.20 mole) of aspartic acid in 300 mL 
of 3 M Na2 C03 was added 202 g (1.6 mole) of benzyl 
chloride at room temperature. The mixture was refluxed for 
10 hours. After cooling to room temperature, the mixture 
was extracted with ethyl acetate (2x1SO mL). The combined 
extracts were dried over MgSO 4 and then filtered. Solvent 
was removed from the filtrate with a rotary evaporator and 
benzyl alcohol was removed at 60° C./0.5 mm Hg to yield 
93.02 g (0.18 mole, 94%) of a light brown oil: R_r0.74 
(Et0Ac:hexane=1:4); 1 H NMR (CDC13 ) 02.82 (ddd, 2H, 
~-CH2), 3.6S (dd, 4H, Ph-CH2-N), 3.97 (t, lH, a-CH), 
S.08 (m, 4H, COO-CH2-PhY,-7.28 (m, 20H, aromatic H). 
FABMS (calculated fofC32H31N04 , 493) m/e 494 (M++l). 
The crude product was used for the next reaction without 
further purification. 
2-(N,N-Dibenzylamino )butane-1,4-diol (38) [Gmeiner, 
P., Junge, D. and Kartner, A J. Org. Chem S9, 6766-6776 
(1994) incorporated herein by reference]. To a stirred solu-
tion of 19.40 g (0.039 mole) of 37 in 60 mL of anhydrous 
THF was added a solution of LiAlH4 in THF in 4 portions 
(0.46 g, 0.012 mole in 20 mL for each portion) at S0 C. The 
resulting mixture was stirred at room temperature for 1 hour 
under an argon atmosphere and then allowed to stand at 
room temperature overnight to permit the lithium salt to 
precipitate. The organic layer was poured into a beaker 
containing 300 mL Et2 0. A saturated aqueous Na2S04 
solution was added with stirring to the ether solution drop-
wise until gas evolution ceased. The resulting mixture was 
stirred for S minutes and then filtered. The solvent was 
butanol (39) [Gmeiner, P., Junge, D. and Kartner, A J. Org. 
Chem. S9, 6766-6776 (1994) incorporated herein by 
reference]. To a solution of 3.61 g (0.012 mole) of 38 in 40 
mL of DMF was added sequentially at S0 C. solutions of 
15 2.36 g (0.016 mole) of t-butyldimethylsilyl chloride in 20 
mL of DMF and 1.77 g (0.026 mole) of imidazole in 20 mL 
of DMF. After stirring the resulting mixture at the same 
temperature for 3 hours under anhydrous conditions, SO mL 
of saturated aqueous NH4 Cl solution was added and the 
20 niixture was extracted with Et2 0 ( 4xSO mL). The combined 
extracts were dried over MgS04 and filtered. The solvent 
was removed in vacuo and the crude residue was purified by 
gel chromatography (EtOAc:hexane=l:S) to give 2.71 g 
(0.0068 mole, S6%) of a colorless oil: R1=0.31 
25 (Et0Ac:hexane=1:4); 1 H NMR (DMSO-d6) o-0.22 (s, 6H, 
Si-CH3), 0.62 [s, 9H, Si-C(CH3h], 1.38 (m, lH, ~-CH), 1.S3 
(m, lH, ~-CH), 3.17 (s, lH, a-CH), 3.30 (m, 2H, -C 
H2-0Si-), 3.46 (m, 6H, Ph-CH2-N, CH2-0H), 4.22 {t;- lH, -OH), 6.98-7.16 (m, lOH, aromatic H); FABMS 
30 (calculated for C24H38N02 Si, 400.2672) m/e 400.2639 (M++l). 
2-(N,N-Dibenzylamino )-4-[( t-butyldimethylsilyl)oxy] 
butanal ( 40) [ Gmeiner, P., Junge, D. and Kartner, A J. Org. 
Chem. S9, 6766-6776 (1994) incorporated herein by 
35 reference]. To a solution of 2.18 g (28 mmol) of DMSO in 
S mL of CH2 Cl2 , solutions of 1.78 g (14 mmol) of oxalyl 
chloride in S mL of CH2 Cl2 and 4.80 g (12 mmol) of 39 in 
20 mL of CH2 Cl2 were added sequentially at - 78° C. After 
stirring at the same temperature under an argon atmosphere 
40 for 30 minutes, 6.07 g (60 mmol) of NEt3 in 60 mL of Et2 0 
was added in one portion. The mixture was stirred for 10 
minutes, washed with saturated aqueous NaHC03 solution 
(2x40 mL) and 1 M NaHS04 solution. The organic layer 
was dried over MgSO 4 and filtered. The solvent was 
45 removed from the filtrate with a rotary evaporator and the 
residue was dried under reduced pressure to give 4.44 g (11 
mmol, 93%) of a colorless oil: R_r0.57 (EtOAc:hexane= 
1:4); 1 H NMR (DMSO-d6) o-0.06 (s, 6H, Si-CH3), 0.76 [s, 
9H, Si-C(CH3) 3 ], 1.86 (m, 2H, ~-CH2), 2.81 (m, 2H, -CH 
50 1-0Si-), 3.61 (m, SH, a-CH, Ph::_CH2-N), 7.28 (m, 
lOH, aromatic H), 9.70 (s, lH, aldehyde H); FABMS 
(calculated for C24H36N02 Si, 398.2S1S) m/e 398.2S1S 
(M++l). 
3-(N ,N-Dibenzylamino )-S-[ (t-butyldimethylsilyl)oxy ]-2-
55 [(trimethylsilyl)oxy ]pentanenitrile ( 41). A mixture of 3.94 g 
(10 mmol) of 40 and 1.37 g (14 mmol) of trimethylsilyl 
cyanide was stirred at room temperature overnight and then 
dried in vacuo for 24 hours to give a quantitative yield of 41 
as a light brown oil (racemic mixture): R_r0.64 
60 (Et0Ac:hexane=1:4); 1 H NMR (CDC13 ) o0.078 (m, lSH, 
Si-CH3), 0.8S [s, 9H, Si-C(CH3h], 1.87 (m, 2H, ~-CH2), 
3.11 (m, lH, a-CH), 3.78 (m,6H, -CH2-0Si-, Ph-C 
H2-N), 4.44 [dd, lH, -CH(CN)-OSi-], 7.20-7.41 (m, 
lOH, aromatic H); FABMS (calculated for C28H45N2 0 2Si2 , 
65 497.3020) m/e 497.2999 (M++l). 
N -(2-Phenylethyl)-3-(N ,N -dibenzylamino )-2,S-
dihydroxypentamide ( 42). A solution of S.52 g (11 mmol) of 
US 6,235,929 Bl 
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41 in 10 mL of concentrated HCl was stirred at room 
temperature for I hour. Excess HCI was removed under 
reduced pressure and the residue was dried in vacuo over-
night to give a brown solid of 3-(N,N-dibenzylamino)-2,S-
dihydroxypentanoic acid: FABMS (calculated for 5 
C19H23N04, 329) m/e 330 (M++l). This crude product was 
dissolved in lS mL of DMF. Upon stirring the solution in an 
ice bath, 1.30 g (13 mmol) of triethylamine was added and 
the mixture was stirred for 10 minutes. To this mixture was 
sequentially added 1.62 g (12 mmol) of HOBt in S mL of 10 
DMF, 2.00 g (16 mmol) of phenethylamine, 2.72 g (13 
mmol) of DCC in S mL of DMF. The resulting solution was 
stirred at 10° C. for 72 hours. The mixture was heated until 
the solids dissolved (approximately at 8S 0 C.) and allowed 
to stand 10° C. overnight. The mixture was then filtered to 15 
remove DCU. Solvent was removed from the filtrate under 
reduced pressure. Ethyl acetate (200 mL) was added to the 
residue and the solution was sequentially washed with 10% 
Na2C03 (2x100 mL), distilled water (100 mL), and satu-
rated NaCl (100 mL). After drying over MgS04, the solution 20 
was filtered and ethyl acetate was removed from the filtrate 
with a rotary evaporator. The crude residue was purified by 
gel chromatography (Et0Ac:hexane=4:1) to give two enan-
tiomers; first enantiomer (2.63 g, 6.8 mmol, SS% yield, a 
yellow hygroscopic solid): R_r0.43 (Et0Ac:hexane=4:1); 25 
1H NMR (DMSO-d6) ol.33 (m, lH, ~-CH), 1.86 (m, lH, 
~-CH), 2.69 (t, 2H, C-CH2-Ph), 2.97 (m, lH,a-CH), 3.23 
(m, 4H, CH2-0H, CONH-CH2-), 3.50 (d, 2H, Ph-C 
H2-N), 3.81 (d, 2H, Ph-CH2 N), 4.26 (t, lH, CH2-0 
H), 4.36 (d, lH, CH-OH), S.66 (d, lH, CH-OH), 7.23 (m, 30 
lSH, aromatic H), 7.8S (t, lH, CONH); FABMS (calculated 
for C27H33N20 3, 433) m/e 433 (M++l). Second enantiomer 
(0.87 g, 2.0 mmol, 18% yield, a yellow oil): Rf =0.21 
(Et0Ac:hexane=4:1); 1H NMR (DMSO-d6) ol.72 (m, 2H, 
~-CH), 2.73 (t, 2H, C-CH2-Ph), 2.99 (q, lH, a-CH), 3.32 35 
(m, 4H, CH2-0H, CONH-CH2-), 3.52 (d, 2H, Ph-C 
H2-N), 3.82 (d, 2H, Ph-CH2 N), 3.9S (t, lH, CH2-0 
H), 4,3S (d, lH, CH-OH), S,49 (d, lH, CH-OH), 7.22 (m, 
lSH, aromatic H), 7.82 (t, lH, CONH); FABMS (calculated 
38 
mixture) in 30 mL of methanol, 1.2S g of 20% Pd(OH)2 in 
SO mL of methanol was added. The mixture was hydroge-
nated at room temperature for 22 hours and then filtered 
through two layers of filter paper. Methanol was removed 
from the filtrate with a rotary evaporator. The residue was 
dried in vacuo overnight to give 2.74 g (11 mmol, 100%) of 
a white solid ( enantiomeric ratio=3: 1): 1H NMR (DMSO-d6) 
ol.36 (m, 2H, ~-CH2), 2.71(m,2H, C-CH2-Ph), 2.9S (dt, 
lH, a-CH), 3.34 (m, SH, CH2-0H, CONH-CH2-, C 
H-OH, CH2-0H, -NH2)-:3.67 (d, 0.33H, CH-OH), 
3.74 (d, 0.66H, CH-OH), 7.2S (m, SH, aromatic H), 7.78 
(t, lH, CONH); FABMS (calculated for C13H21N20 3, 
2S3.1SS2) m/e 2S3.1S48 (M+ +1). 
N-(3-Phenylpropyl)-3-amino-2,S-dihydroxypentamide 
(4S). This was prepared in a manner identical to that for 44, 
except using 4.70 g (10 mmol) of 43 (enantiomeric mixture) 
to give 2.80 g (10 mmol, 100%) of a white solid 
(enantiomeric ratio=2:1): 1H NMR (DMSO-d6) ol.43 (m, 
2H, 4-CH2), 1.69 (m, 2H, CONH-CH2-CH2-CH2-Ph), 
2.52 (m;-3H, C-CH2-Ph, a-CH), 3.06 (m;-5H, CH2-0H, 
CONH-CH2-, CH- OH), 3.49 (m, lH, CH2-0H), 3.53 
(br, 2H, -NH2), 3.69 (d, 0.33H, d, CH-OH), 3.78 (d, 0.66H, 
CH-OH), 7.21 (m, SH, aromatic H), 7.84 (t, lH, t, CONH). 
FABMS (calculated for C14H23N20 3, 267.1709) m/e 
267.1699 (M++l). 
N-(2-Phenylethyl)-3-(N-
be nzy loxycarbony lalany lamina )-2,S-dihydroxype ntamide 
(46). Upon stirring a solution of 2.71 g (10.74 mmol) of 44 
(mixture of enantiomers) in 10 mL of DMF in an ice bath, 
1.08 g (8 mmol) of HOBt and 2.00 g (8.9S mmol) of 
N-benzyloxycarbonylalanine in 10 niL of DMF, and 2.21 g 
(10.74 mmol) of DCC in 10 mL of DMF were added 
sequentially. The mixture was stirred at 10° C. for 24 hours. 
The mixture was heated until the solids dissolved (90° C.). 
The solution was stood at 10° C. overnight and filtered to 
remove DCU. Solvent was removed from the filtrate under 
reduced pressure. Ethyl acetate (100 mL) was added to the 
residue and the solution was washed with saturated NaHC03 
(SO mL), lM HCl (SO mL) and distilled water (SO mL). 
for C27H33N20 3, 433) m/e 433(M+ +1). 
N-(3-Phenylpropyl)-3-(N ,N-dibenzylamino )-2,S-
dihydroxypentamide (43). This was prepared in a manner 
identical to that for 42, except using 3-phenyl-1-
propylamine, 3.97 g (0.019 mole) instead of phenethylamine 
40 Methanol (20 mL) and MgS04 were added to the final 
solution, which was allowed to stand at room temperature 
overnight, and filtered. Solvent was removed from the 
filtrate with a rotary evaporator and the residue was recrys-
to give two enantiomers; first enantiomer (3.40 g, 7.6 mmol, 45 
47% yield, a yellow hygroscopic solid): R_r0.30 
(Et0Ac:hexane=4:1); 1H NMR (DMSO-d6) ol.39 (m, lH, 
~-CH), 1.68 (p, 2H, CONH-CH2-CH2-CH2-Ph), 1.88 
(m, lH, ~-CH), 2.52 (t, 2H, C-CH2 Ph), 2.97 (d, lH, 
a-CH), 3.07 (q, 2H, CH2-0H), 3.19 (m, lH, CONH-C 50 
H2-), 3.SS (m, 3H, Ph-CH2-N, CONH-CH2-), 3.81 
(d, 2H, Ph-CH2-N), 4.26(1, lH, CH2-0H), 4.36 (d, lH, 
CH-OH), S.6T(d, lH, CH-OH), 7.24 (m, lSH, aromatic 
H), 7.8S (t, lH, CONH); FABMS (calculated for 
C28H35N20 3, 447.2648) m/e 447.2680 (M++l). Second 55 
enantiomer (1.3S g, 3.0 mmol, 19% yield, a yellow oil): 
R_r0.10 (Et0Ac:hexane=4:1); 1H NMR (DMSO-d6) ol.73 
(m, 4H, ~-CH2, CONH-CH2-CH2-CH2-Ph), 2.57 (m, 
2H, C-CH2-Ph), 3.10 (m, 4H, a-CH, CH2-0H, 
CONH-CH2-), 3.38 (m, lH, CONH-CH2-);-3°.53 (d, 60 
2H, Ph-CH2-N), 3.86 (d, 2H, Ph-CH2-N), 3.97 (t, lH, 
CH-OH),4,3S (t, lH, CH2-0H), S,43(d, lH, CH-OH), 
7.22 (m, lSH, aromatic H), 7.80 (t, lH, CONH); FABMS 
(calculated for C28H35N20 3, 447.2648) m/e 447.2640 (M+ + 
tallized from Et0Ac:methanol:hexane=2:0.5:1 to give 2.82 
g (6.16 mmol, 68%) of a white solid (R_r0.34,0.27, 
EtOAc:MeOH=lO: 1, enantiomer ratio=3.8:1.0): mp 
142-144° C.; 1H NMR (DMSO-d6) ol.18 (d, 3H, Ala ~-C 
H3), 1.44 (m, 2H, pentamide 4-CH2), 2.72 (t, 2H, C-C 
H2-Ph), 3.31 (m, 4H, CH2-0H, CONH-CH2-), 3.87 
(dd, lH, pentamide 3-CH};4.08 (m, 2H, Ala a-CH, penta-
mide 2-CH), 4.27 (t, lH, CH2-0H), S.01 (dd, 2H, Ph-C 
H2-0CO), S.77 (d, 0.79H, CH-OH), S.86 (d, 0.21H, 
CH-OH), 7.26 (m, lOH, aromatic H), 7.41 (d, lH, CONH), 
7.57 (d, lH, CONH), 7.84 (t, lH, CONH); FABMS 
(calculated for C24H32N30 6 , 4S8.2291) m/e 4S8.232S (M+ + 
1). 
N-(3-Phenylpropyl)-3-(N-
be nzy loxycarbony lalany lamina )-2,S-dihydroxype ntamide 
(47). This was prepared in a manner identical to that for 46, 
except using 2.00 g (7.5 mmol) of 4S (enantiomeric mixture) 
to give 1.62 g (3.4 mmol, 4S%) of a white solid (enantiomer 
ratio=3:1):R_r0.09 (EtOAc); mp 109-119° C.; 1H NMR 
(DMSO-d6) ol.18 (d, 3H, Ala ~-CH3), 1.SO (m, 2H, penta-
mide 4-CH2), 1.70 (p, 2H, CH2-CH2-CH2Ph), 2.54 (t, 
1). 
N-(2-Pheny le thy 1)-3-amino-2,S-dihydroxypentamide 
( 44). To a solution of 4.71 g (11 mmol) of 42 ( enantiomeric 
65 2H, CH2-CH2-CH2Ph), 3.09 (m, 2H, N-CH2-CH2-
CH2Ph), 3.31 (m, 2H, pentamide S-CH2), 3.88 (m, lH, Ala 
a-CH), 4.08 (m, 2H, pentamide 2-CH, 3-CH), 4.30 (t, lH, 
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pentamide 5-CH2-0H), 5.01 (dd, 2H, Ph-CH2-0CO), 
5.73, 5.81 (d, 0.75H, pentamide 2-CH-OH), 5.81 (d, 
0.25H, pentamide 2-CH-OH), 7.31 (m, llH, aromatic 
CH's, CONH-Ala), 7.57 (d, lH, PhCH20CONH), 7.85 (t, 
lH, CONHCH2-CH2-CH2Ph); FABMS (calculated for 5 
C25H34N30 6, 472.2448) m/e 472.2411 (M++l). 
N-(2-Phenylethyl)-3-(N-
b e nzylo xyc arb on y 1 val yl al an yl amino )-2, 5 -
dihydroxypentamide ( 48). This was prepared in a manner 
identical to that for 46, except using 1.28 g (4.0 mmol) of 10 
Cbz-Val-Ala-OH to give 0.92 g (1.1 mmol, 44%) of a 
white solid ( enantiomeric ratio could not be determined due 
to the overlap of the pentamide 2-CH-OH peaks in the 1H 
MNR spectrum): mp 218-220° C.; 1H NMR (DMSO-d6) 
o0.82 (dd, 6H, Val ~-CH3's), 1.17 (d, 3H, Ala ~-CH3), 1.43 15 
(m, 2H, pentamide 4-CH2), 1.95 (m, lH, Val ~-CH), 2.71 (t, 
2H, CONH-CH2-CH2Ph), 3.29 (m, 4H, pentamide 5-C 
H2, N-CH2-CH2Ph)~.85 (m, 2H, Ala, Val a-CH), 4.08 
(m, lH, pentamide 3-CH), 4.26 (m, 2H, pentamide 2-CH, 
5-CH2-0H), 5.01 (s, 2H, PhCH20CONH), 5.76 (d, lH, 20 
pentamide 2-CH-OH), 7.29 (m, llH, aromatic CH's, 
Ala-NH), 7.61 (d, lH, PhCH20CONH), 7.82 (t, lH, CON 
H-CH2-CH2Ph), 7.95 (d, lH, Val-NH); FABMS 
(calculated for C29H41 N40 7, 557.2975) m/e 557.2935 (M+ + 
40 
CONH); FABMS (calculated for C30H46N30 6Si, 572.3156) 
m/e 572.3151 (M++l). 
N-(3-Phenylpropyl)-3-(N-
benzy loxycarbonylalanylamino )-5-t-buty ldimethy lsil yloxy-
2-hydroxypentamide (51). This was prepared in a manner 
identical to that for 50, except using 1.59 g (3.4 mmol) of 47 
to give 1.56 g (2.6 mmol, 78%) of a colorless oil 
(enantiomeric ratio=2.2:1): R_r0.43, 0.38 (EtOAc); 1H 
NMR (DMSO-d6) o-0.03 (s, 6H, Si-CH3's), 0.78 (s, 9H, 
Si-t-Bu), 1.17 (d, 3H, Ala ~-CH3), 1.50 (m, 2H, pentamide 
4-CH2), 1.69 (m, 2H1 CONHCH2-CH2-CH2Ph), 2.53 (t, 2H,CONHCH2-CH2-CH2-Ph)~3.10 (m, 4H, C 
H2-0H, CONH-CH2-), 3.85 (dd, lH, pentamide 3-CH), 
4,07 (m, 2H, Ala a-CH, pentamide 2-CH), 5.00 (s, 2H, 
Ph-CH2-0CO), 5.73 (d, 0.8H, pentamide 2-CH-OH), 
5.82 (d-;-0.2H, pentamide 2-CH-OH), 7.18 (m, llH, aro-
matic 1, CONH), 7.55 (d, lH, CONH), 7.86 (t, lH, t, CON 
H); FABMS (calculated for C31H48N30 6Si, 586.3312) m/e 
586.3354 (M+ +1). 
N-(2-Phenylethyl)-3-(N-
b e nzylo xyc arb on yl val yl al an yl amino )-5 -t-
butyldimethylsilyloxy-2-hydroxypentamide (52). This was 
prepared in a manner identical to that for 50, except using 
0.63 g (1.1 mmol) of 48 to give 0.54 g (0.8 mmol, 71 % ) of 
1). 
N -(3-Phenylpropyl)-3-(N -
25 a solid ( enatiomeric ratio was not determined): R_r0.27 
(EtOAc); 1H NMR (DMSO-d6) o-0.04 (s, 6H, Si-CH3's), 
0.83 (m, 15H, Si-t-Bu, Val ~-CH3's), 1.18 (d, 3H, Ala 
~-CH3), 1.50 (m, 2H, pentamide 4-CH2), 1.95 (m, lH, Val 
be nzylo xyc arb on y 1 val yl al an yl amino )-2, 5 -
dihydroxypentamide ( 49). This was prepared in a manner 
identical to that for 46, except using 2.98 g (9,2 mmol) of 
Cbz-Val-Ala-OH and 2.71 g (10.17 mmol) of 45 to give 30 
2.37 g (4.15 mmol, 44%) of a white solid (enantiomeric ratio 
could not be determined): R_r0.07 (EtOAc); mp 192-193° 
C.; 1H NMR (DMSO-d6) o0.82 (dd, 6H, Val ~-CH3's), 1.17 
(d, 3H, Ala ~-CH3), 1.50 (m, 2H, pentamide 4-CH2), 1.70 
(m, 2H, CONH-CH2-CH2-CH2Ph), 1.94 (m, lH, Val 35 
~-CH), 2.53 (t, 2H, CONH-CH2-CH2-CH2Ph), 3.07 
(m, 2H, CONH-CH2-CH2-CH2Ph), 3.32 (m-;2H, penta-
mide 5-CH2), 3.86(m, 2H, Ala, Val a-CH), 4.10 (m, lH, 
pentamide3-CH), 4.28 (m, 2H, pentamide 2-CH, 5-CH2-0 
H), 5.00, (s, 2H, PhCH20CONH), 5.73 (d, lH, pentamide 40 
2-CH-OH), 7.24 (m,llH, aromatic CH's,Ala-NH), 7.62 
~-CH), 2.72 (t, 2H, CONHCH2-CH2Ph), 3.28 (m, 2H, 
CONHCH2-CH2Ph), 3.48 (m, 2H, pentamide 5-C 
H2-0HY,-3.87 (m, 2H, Ala, Val a-CH), 4.12 (m, lH, 
pentamide 3-CH), 4,32 (m, lH, pentamide 2-CH, 5.01 (s, 
2H, Ph-CH2-0CO), 5.74 (d, lH, pentamide 2-CH-OH), 
7.25 (m, llH, aromatic H, CONH), 7.62 (t, lH, CONH), 
7.82 (t, lH, CONH), 7.93 (d, lH, CONH); FABMS 
(calculated for C35H55N40 7Si, 671.3840) m/e 671.3895 
(M++l). 
N-(3-Phenylpropyl)-3-(N-
b e nzylo xyc arb on yl val yl al an ylamino) -5 -t-
butyldimethylsilyloxy-2-hydroxypentamide (53). This was 
prepared in a manner identical to that for 50, except using 
1.00 g (1.7 mmol) of 49 to give 1.01 g (1.4 mmol, 84%) of 
a solid ( enatiomeric ratio was not determined): R_r0.42, 0.30 
(EtOAc); 1H NMR (DMSO-d6) o-0.05 (s, 6H, Si-CH3's), 
(d, lH, PhCH20CONH), 7.83 (t, lH, CON 
H-CH2-CH2Ph), 7.97 (d, lH, Val-NH); FABMS 
(calculated for C30H43N40 7, 571.3132) m/e 5571.3169 
(M++l). 
N-(2-Phenylethyl)-3-(N-
45 0.81 (m, 15H, Si-t-Bu, Val ~-CH3's), 1.17 (d, 3I:r,-Ala 
~-CH3), 1.57 (m, 2H, pentamide 4-CH2), 1.70 (m, 2H, 
CONHCH2-CH2-CH2Ph), 1.95 (m, lH, Val ~-CH), 2.53 
(t, 2H, CONHCH2-CH2-CH2Ph), 3.10 (m, 2H, CONHC 
benzy loxycarbony lalany lamina )-5-t-buty ldimethy lsil y loxy-
2-hydroxypentamide (50). Upon stirring a solution of 46 
(1.13 g, 2.5 mmol) in 7 mL of DMF, t-butyldimethylsilyl 
chloride (0.745 g, 3.0 mmol) and imidazole (0.37 g, 5.5 50 
mmol) were added sequentially. The resulting mixture was 
stirred at room temperature for 47 hours. Saturated NH4Cl 
solution (20 mL) was added and the mixture stirred at room 
temperature for 5 minutes and was extracted with EtOAc 
H2-CH2-CH2Ph), 3.51 (m, 2H, pentamide 5-CH2-0H), 
3.87 (m, 2H, Ala, Val a-CH), 4.12 (m, lH, pentamide 3-C 
H), 4,32 (m, lH, pentamide 2-CH), 5.01 (s, 2H, Ph-C 
( 4x25 mL). The combined extracts were dried over MgS04 55 
and filtered. Solvent was removed from the filtrate with a 
H2-0CO), 5.73 (d, IH, pentamide 2-CH-OH), 7.25 (m, 
llH, aromatic H, CONH), 7.65 (d, lH, CONH), 7.80 (t, lH, 
CONH), 7.93 (d, lH, CONH); FABMS (calculated for 
C36H57N40 7Si, 685.0) m/e 685.3 (M++l). 
General Procedure for Compounds 54-57 (Cbz-Ala-
Asp-CONH-CH2CH2Ph, 54). Upon stirring a solution of 
50 (1.10 g, 1.9 mmol) in CH2Cl2 (6 mL) and Et20 (2 mL) 
with cooling (ice bath), chromiium trioxide (0.38 g, 3.8 
rotary evaporator and the crude product was purified by gel 
chromatography (EtOAc) to give 0.80 g (1.40 mmole, 56%) 
of a white solid (enatiomeric ratio=3.2:1): R_r0.51, 0.41 
(EtOAc); 1H NMR (DMSO-d6) o0.02 (s, 6H, Si-CH3's), 
0.84 (s, 9H, Si-t-Bu), 1.20 (d, 3H, Ala ~-CH3), 1.52 (~2H, 
pentamide 4-CH2), 2.72 (t, 2H, C-CH2-Ph), 3.38 (m, 4H, 
CH2-0H, CONH-CH2-), 3.85 (dd, lH, pentamide 3-C 
HY,-4,07 (m, 2H, Ala a-CH, pentamide 2-CH, 5.00 (s, 2H, 
Ph-CH2-0CO), 5.75 (d, 0.76H, pentamide 2-CH-OH), 
5.86 (c:r,- 0.24H, pentamide 2-CH-OH), 7.31 (m, llH, 
aromatic H, CONH, 7.45 (d, lH, CONH), 7.74 (t, lH, t, 
60 mmol) was added and the mixture was stirred at 5° C. under 
an argon atmosphere for 2 hours. The solvent was removed 
from the mixture under reduced pressure. Acetic acid (7 
mL), H20 (0.8 mL), and Cr03 (0.77 g, 7.6 mmol) were 
added and the mixture was stirred at room temperature for 
65 3 hours. The resulting mixture was diluted with EtOAc/ 
isopropanol (10:1, 100 mL), dried over MgS04, and filtered 
through silica gel. The solvent was removed from the filtrate 
US 6,235,929 Bl 
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and the crude product was purified by gel column chroma-
tography (EtOAc) to give 0.16 g (0.34 mmol, 17% yield) of TABLE III-continued 
a colorless oil (R_r0.54, EtOAc). 
no. mp(° c.) 
12 6S-67 
13 116-117 
14 13S-137 
lS 128-129 
24 nd 
2S nd 
26 181-182 
Physical properties of a-Keto Amides. 
TABLE III s 
FABMS m/e (M+ + 1) 
Physical properties of a-Keto Amides. 
Formula 
C18H24N206 
C19H26N206 
C19H20N206 
C21H22N206 
C13H17N2 0 4Cl 
C14H19N2 0 4Cl 
C20H22N20 6 S 
no. mp(° c.) Formula Calculated Found 
FABMS m/e (M+ + 1) 10 27 120-121 C20H27N306 406.1978 406.1993 
Calculated 
36S.1713 
379.1869 
373.1399 
399.1SS6 
26S.1188 
279.134S 
419.1277 
28 147-149 C28H34N407 S39.2S06 S39.2487 
Found Anal. 29 160-162 C29H36N407 SS3.2662 SS3.26S9 
31 21S-216 C30H3sN407 S67.2819 S67.284S 
36S.1738 C,H,N lS 33 198-199 C30H37N4 0 7Cl 601.2429 601.246S 
379.1860 C,H,N 3S 140-142 C32H41Ns09 640.2982 640.2963 
36 161-163 C33H43Ns09 6S4.3139 6S4.3110 373.1368 C,H,N 
S4 nd C24H27N307 470.1927 479.1936 
399.1S79 C,H,N 
SS nd C2sH29N307 484.2084 484.21S4 
26S.1178* C,H,N 20 S6 13S-137 C29H36N40s S69.2611 S69.2634 
279.1372* C,H,N S7 nd C3aH3sN40s S83.2768 S83.2781 
419.1263 C,H,N 
*[M + H-HC!]' 
TABLE IV 
Proton NMR Data (DMSO-d6) for Selected Compounds. 
no. major signals 
12 1.42(s, 9H, Boe CH3 's), 2.74(t, 2H, CH2 Ph), 2.9S(obs, 2H, 13-CH2), 3.30 
(m, 2H, NHldh), 4.82(m, lH, a-CH), 7.24(m, SH, aromatic CH's), 8.6S(br, 
lH, COOH). 
13 1.38(s, 9H, Boe CH3 's), 1.67(t, 2H, CH~CH2Ph), 2.S7(obs, 2H, 
CH2Ph), 2.61(m, lH, 1 of 13-CH2), 3.ll(m, 3H, NHldh & 1 of 13-CH2), 4.26 
(m, lH, a-CH), 7.0l(d, lH, urethane NH), 7.21(m, SH, aromatic CH's), 7.8S 
(br, lH, amide NH), 8.80(br, lH, COOH). 
lS 2.68(m, 4H, 13-CH2 , CH~Ph), 3.31(m, 2H, CONHldhCHo), S.Ol(m, 
3H, a-CH°' PhldhOCO), 7.2S(m, lOH, aromatic H), 7.7S(d, lH, OCONH), 
8.78(t, lH, keto amide NH), 12.46(br, lH, COOH). 
24 2.73(t, 2H, CH2Ph), 3.37(m, 4H NHldh & 13-CH2), 3.97(m, lH, a-CH), 
7.24(m, SH, aromatic CH's), 8.61(br, 3H, NH3+), 8.7S(t, lH, amide NH). 
2S 1.72(m, 2H, CH~CH2Ph), 2.S8(t, 2H, CH2Ph), 2.80(ABX, 2H, 13-CH2), 
3.09(m, 2H, NHldh), 4.00(m, lH, a-CH), 7.22(m, SH, aromatic CH's), 8.S7 
(br, 3H, NH3+), 8.79(br, lH, amide NH). 
26 2.67(m, 4H, CH2 Ph & 13-CH2), 3.2S(q, 2H, NHldh), 4.60(q, lH, a-CH), 
S.08(s, 2H, benzyl CH2), 7.31(m, lOH, aromatic CH's), 7.97(br, lH, amide 
NH), 8.17(d, lH, sulfonamide NH), 8.7S(br, lH, COOH). 
27 0.84(d, 6H,(ldh)~CHCH2CO, 1.93(m, 3H, (CH3 ) 2C!iCH2CO, 
PhC~CH2NHCO), 2.73(m, 4H, Asp 13-CH2 , PhCH~NHCO), 3.lS(d, 
2H,(CH3 ) 2 CHldhC0, 3.69(d, 2H, Gly a-CH2), S.06(br, lH, Asp a-CH), 
7.20(m, aromatic CH's), 7.99(t, lH, (CH3 ) 2CHCH2CON!i), 8.22(br, lH, Gly 
amide NH), 8.66(br, lH, a-keto amide NH). 
28 1.14(m, 6H, 2 Ala CH3 's), 2.44(m, 6H, PhldhCH2CO, PhldhCH2 NHCO, 
Asp 13-CH2 's), 3.27(m, SH, PhldhCH2CO, PhCH~NHCO, COOH), 4.26 
(m, 2H, Ala a-CH), S.OO(br, lH, Asp a-CH), 7.20(m, lOH, aromatic CH's), 
8.03(m, 3H, Ala, Asp amide NH's), 8.63(br, lH, a-keto amide NH). 
29 0.80(m, 6H, Val CH3 's), 1.91(m, lH, Val 13-CH), 2.40(m, 4H, 
PhldhCH2 CONH, COCONHCH~Ph), 2.77(m, 6H, Asp 13-CH2 's, 
PhCH~CONH, COCONHldhCH2 Ph), 3.72(m, 2H, Gly a-CH2), 4.09 
(m, lH, Val a-CH), S.lS(br, lH, Asp a-CH), 7.21(m, aromatic CH's), 7.93 
(m, 3H, Val, Gly, Asp amide NH), 8.71(br, lH, a-keto amide NH), 12.38(br, 
lH, COOH). 
31 0.7S(m, 6H, Val CH3 's), 1.16(m, 3H, Ala CH3), 1.91(m, lH, Val 13-CH), 
2.4S(m, 4H, Asp 13-CH2 's, PhCH~CO), 2.76(m, 6H, PhCH2CH2NHCO, 
PhldhCH2 CO), 4.14(t, lH, Val a-CH), 4.28(t, lH, Ala a-CH), S.03,(br, lH, 
Asp a-CH), 7.20(m, lOH, aromatic CH's), 7.8S(d, lH, Val amide NH), 8.00 
(d, lH, Ala amide NH), 8.26(br, lH, Asp amide NH), 8.68(br, lH, a-keto 
amide NH), 12.42(br, lH, COOH). 
33 0.74(m, 6H, Val CH3 's), 1.16(m, 3H, Ala CH3), 1.89(m, lH, Val 13-CH), 
2.43(m, 4H, Asp 13-CH2 +s, PhCH~CO), 2.72(m, 6H, PhCH2CH2NHCO, 
PhldhCH2 CO), 4.13(t, lH, Val a-CH), 4.28(t, lH, Ala a-CH), S.04,(br, lH, 
Anal. 
C,H,N 
C,H,N 
C,H,N 
C,H,N 
C,H,N 
C,H,N 
C,H,N 
C,H,N 
C,H,N 
C,H,N 
C,H,N 
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TABLE IV-continued 
Proton NMR Data (DMSO-d6) for Selected Compounds. 
no. major signals 
Asp a-CH), 7.20,(m, 9H, aromatic CH's), 7.86(d, lH, Val amide NH), 8.00(d, 
lH, Ala amide NH), 8.26(br, lH, Asp amide NH), 8.69(br, lH, a-keto amide 
NH), 12.48(br, lH, COOH). 
3S 0.76(m, 6H, Val CH3 's), 1.19(d, 3H, Ala CH3), 1.7S(s, 3H, Ac CH3), 1.94 
(m, lH, Val 13-CH), 2.68(m, 6H, CH2Ph, Asp & Tyr 13-CH2's), 3.26(q, 2H, 
NHECH2EE), 4.19 & 4.48(m, 4H, a-CH's), 6.62 & 7.02(2 x d, 4H, Tyr aromatic 
CH's), 7.21(m, SH, phenyl aromatic CH's), 7.7S(t, lH, amide NH), 7.84(d, 
lH, amide NH), 7.92(d, lH, amide NH), 8.07(m, 2H, amide NH's), 9.lS(br, 
lH, Tyr OH). 
36 0.77(2 x d, 6H, Val CH3 's), 1.21(d, 3H, Ala CH3), 1.66(m, 2H, 
CH£1LCH2Ph), 1.7S(s, 3H, Ac CH3), 1.9S(m, lH, Val 13-CH), 2.70(m, 6H, 
CH2Ph, Asp & Tyr 13-CH2+s), 3.0S(app q, 2H, NHldi,), 4.20 & 4.48(m, 4H, 
a-CH's), 6.63 & 7.02(2 x d, 4H, Tyr aromatic CH's), 7.2S(m, SH, phenyl 
aromatic CH's), 7.83 & 8.08(m, SH, amide NH's), 9.18(br, lH, Tyr OH), 
11.06(br, lH, COOH). 
S4 1.22(d, 3H, Ala CH3), 2.7S(t, 2H, C----Qh-Ph), 2.99(t, 2H, Asp 13-CH2), 3.34 
(m, 2H, CONH--CJ:h--CH2Ph), 4.32(m, 3H, Ala a-CH, PhCH20CON!i, Asp a-
CH), S.OO(s, 2H, Ph--CJ:h-OCO), 7.28(m, lOH, aromatic H), 7.66(d, lH, Asp 
amide NH), 8.99(t, lH, keto amide NH), 10.89(s, lH, COOH). 
SS* 1.38(d, 3H, Ala CH3), 1.87(m, 2H, CONHCH2--CJ:h--CH2Ph), 2.64(t, 2H, C-
CJ:h-Ph), 3.12(m, 2H, Asp 13-CH2), 3.33(m, 2H, CONH--CJ:h--CH2Ph), 4.52 
(m, 3H, Ala a-CH, CONH, Asp a-CH), S.09(dd, 2H, Ph--CJ:h-OCO), S.78(d, 
lH, PHCH20CONH), 7.32(m, 11H, aromatic H, keto amide NH), 9.66(s, lH, 
COOH). 
S6* 0.93(dd, 6H, Val CH3 's), 1.36(d, 3H, Ala CH3), 2.09(m, lH, Val 13-CH), 
2.84(t, 2H, CONHCH2--CJ:hPh), 3.lS(m, 2H, Asp 13-CHo), 3.56(dd, 2H, 
CONHCH2--CJ:hPh), 4.08(m, lH, Ala a-CH), 4.Sl(m, lH, Val a-CH), 4.70 
(m, lH, Asp a-CH), S.ll(s, 2H, PhCJ:hOCO), S.7S(d, lH, PhCH20CONH), 
7.26(m, 13H, aromatic CH's, Ala, Asp, amide NH's, a-keto amide NH), 9.7S 
(s, lH, COOH). 
S7 0.84(dd, 6H, Val CH3 's), 1.24(m, 3H, Ma CH3), 1.74(p, 2H, CONHCH2-
CJ:h--CH2Ph), 1.94(m, lH, Val 13-CH), 2.SS(t, 2H, CONHCH2--CH2--CH2Ph), 
2.99(t, 2H, CONHCJ:h--CH2--CH2Ph), 3.12(dd, 2H, Asp 13-CH2), 3.88(m, 
lH, Ala a-CH), 4.41(m, 3H, Asp a-CH, PhCH20CON!i, Val a-CH), S.Ol(s, 
2H, PhCHrOCO), 7.28(m, 11H, aromatic CH's, Val amide NH), 8.24(d, lH, 
Ala amide NH), 8.96(t, lH, a-keto amide NH), 10.8S(br, lH, COOH). 
*Data obtained in CDC13 . 
It is obvious that those skilled in the art may make 
modifications to the invention without departing from the 40 
spirit of the invention or the scope of the subjoined claims 
and their equivalents. 
What is claimed is: 
1. A compound of the formula: 
4S 
or a pharmaceutically acceptable salt, wherein 
M1 represents H, NH2-CO-, NH2-CS-, NH2-
S02-, X-NH-CO-, X2N-CO-, X-NH- so 
CS-, X2N-CS-, X-NH-S02-, X2N-S02-, 
X-CO-, X-CS-, X-502-, X-0-CO, 
X-0-CS-; 
X is selected from the group consisting of C1_10 alkyl, 
cl-10 fiuoroalkyl, cl-10 alkyl substituted with J, cl-10 SS 
fiuoroalkyl substituted with J, 1-admantyl, 9-fiuorenyl, 
phenyl, phenyl substituted with K, phenyl disubstituted 
with K, phenyl tisubstituted with K, naphthyl, naphthyl 
substituted with K, naphthyl disubstituted with K, 
naphthyl trisubstituted with K, C1_10 alkyl with an 60 
attached phenyl group substituted with K, C1_10 alkyl 
with two attached phenyl groups substituted with K, 
cl-10 alkyl with an attached phenoxy group, and cl-10 
alkyl with an attached phenoxy group substituted with 
K on the phenoxy group; 6S 
J is selected from the group consisting of halogen, COOH, 
OH, CN, N02, NH2, C1_10 alkoxy, C1_10 alkylamine, 
C2_12 dialkylamine, C1_10 akyl-0-CO-, C1_10 
alkyl-0-CO-NH-, and C1_10 alkyl-S-; 
K is selected from the group consisting of halogen, C1_10 
alkyl, C1_10 perfiuoroalkyl, C1_10 alkoxy, N02, CN, 
OH, C0 2H, amino, C1_10 alkylamino, C2_12 
dialkylamino, C1_10 acyl, and C1_10 alkoxy-CO-, 
and cl-10 alkyl-S-; 
AA1 andAA2 are the same or different and are side chain 
blocked or unblocked amino acids with the L 
configuration, D configuration, or no chirality at the 
a-carbon selected from the group consisting of alanine, 
valine, leucine, isoleucine, glycine, serine, aspartic 
acid, and glutamic acid; 
AA3 is selected from the group consisting of aspartic acid 
and glutamic acid; 
R3 is selected from the group consisting of C2_3 alkyl with 
a phenyl group attached to the c2-3 alkyl, c3-20 cyclized 
alkyl with an attached phenyl group, C1_20 alkyl with an 
attached phenyl group substituted with K, C1_20 alkyl 
with an attached phenyl group disubstituted with K, 
cl-20 alkyl with an attached phenyl group trisubstituted 
with K, C3_20 cyclized alkyl with an attached phenyl 
group substituted with K, -NH-CH2CH2-( 4-
hydroxyphenyl), and -NH-CH2CH2---(3-indolyl); 
and 
R4 is selected from the group consisting of H, C3_20 alkyl, 
cyclized alkyl, C1_20 alkyl with a phenyl group attached 
to the cl-20 alkyl, c3-20 cyclized alkyl with an attached 
phenyl group, cl-20 alkyl with an attached phenyl 
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group substituted with K, C1_20 aLkyl with an attached 
phenyl group disubstituted with K, C1_20 alkyl with an 
attached phenyl group trisubstituted with K, C3_20 
cyclized alkyl with an attached phenyl group substi-
tuted with K, -NH-CH2CH2---( 4-hydroxyphenyl), 5 
and -NH-CH2CH2-(3-indolyl). 
2. A compound according to claim 1, or a pharmaceuti-
cally acceptable salt thereof, wherein M1 is selected from the 
group consisting of X-CO and X-0-CO, and R4 is H. 
3. A compound according to claim 2, or a pharmaceuti- 10 
cally acceptable salt thereof, wherein X is selected from the 
group consisting of C1_10 alkyl, phenyl, phenyl substituted 
with K, C1_10 alkyl with an attached phenyl group, C1_10 
alkyl with an attached phenyl group substituted with K, and 
R3 is selected from the group consisting of C1_20 alkyl 15 
with a phenyl group attached to the cl-20 alkyl. 
4. A compound of the formula: 
20 
or a pharmaceutically acceptable salt, wherein 
M1 represents H, NH2-CO-, NH2-CS-, NH2-
S02-, X-NH-CO-, X2N-CO-, X-NH-
CS-, X2N-CS-, X-NH-S02-, X2N-S02-, 
X-CO-, X-CS-, X-502-, X-0-CO, 25 
X-0-CS-; 
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OH, C0 2H, amino, C1_10 alkylamino, C2_12 
dialkylamino, C1_10 acyl, and C1_10 alkoxy-CO-, 
and cl-10 alkyl-S-; 
AA1 andAA2 are the same or different and are side chain 
blocked or unblocked amino acids with the L 
configuration, D configuration, or no chirality at the 
a-carbon selected from the group consisting of alanine, 
valine and glycine; 
AA3 is selected from the group consisting of aspartic acid 
and glutamic acid; 
R3 is selected from the group consisting of C2_3 alkyl with 
a phenyl group attached to the c2-3 alkyl, c3-20 cyclized 
alkyl with an attached phenyl group, C1_20 alkyl with an 
attached phenyl group substituted with K, C1_20 alkyl 
with an attached phenyl group disubstituted with K, 
cl-20 alkyl with an attached phenyl group trisubstituted 
with K, C3_20 cyclized alkyl with an attached phenyl 
group substituted with K, -NH-CH2CH2-( 4-
hydroxyphenyl), and -NH-CH2CH2---(3-indolyl); 
and 
R4 is selected from the group consisting of H, C1_20 alkyl, 
c3-20cyclized alkyl, cl-20 alkyl with a phenyl group 
attached to the cl-20 alkyl, c3-20 cyclized alkyl with an 
attached phenyl group, C1_20 alkyl with an attached 
phenyl group substituted with K, C1_20 alkyl with an 
attached phenyl group disubstituted with K, C1_20 alkyl 
with an attached phenyl group trisubstituted with K, 
C3_20 cyclized alkyl with an attached phenyl group 
substituted with K, -NH-CH2CH 2-( 4-
hydroxyphenyl), and -NH-CH2CH2---(3-indolyl). 
X is selected from the group consisting of C1_10 alkyl, 
cl-10 fiuoroalkyl, cl-10 alkyl substituted with J, cl-10 
fiuoroalkyl substituted with J, 1-admantyl, 9-fiuorenyl, 
phenyl phenyl substituted with K, phenyl disubstituted 30 
with K, phenyl trisubstituted with K, naphthyl, naph-
thyl substituted with K, naphthyl disubstituted with K, 
naphthyl trisubstituted with K, C1_10 alkyl with an 
attached phenyl group substituted with K, C1_10 alkyl 
with two attached phenyl groups substituted with K, 
cl-10 alkyl with an attached phenoxy group, and cl-10 
alkyl with an attached phenoxy group substituted with 
5. A compound according to claim 1, or a pharmaceuti-
cally acceptable salt thereof, wherein M1 is selected from the 35 group consisting of X-CO and X-0-CO, and R4 is H. 
K on the phenoxy group; 
J is selected from the group consisting of halogen, COOH, 
OH, CN, N02, NH2 C1_10 alkoxy, C1_10 alkylamine, 
C2_12 dialkylamine: C1_10 alkyl-0-CO-, C1_10 
alkyl-0-CO-NH-, and C1_10 alkyl-S-; 
K is selected from the group consisting of halogen, C1_10 
alkyl, C1_10 perfiuoroalkyl, C1_10 alkoxy, N02, CN, 
6. A compound according to claim 5, a pharmaceutically 
acceptable salt thereof, wherein Xis selected from the group 
consisting of C1_10 alkyl, phenyl, phenyl substituted with K, 
cl-10 alkyl with an attached phenyl group, cl-10 alkyl with 
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an attached phenyl group substituted with K, and 
R3 is selected from the group consisting of C1_20 alkyl 
with a phenyl group attached to the cl-20 alkyl. 
* * * * * 
